<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001832.pub3" GROUP_ID="ARI" ID="065901082416585498" MERGED_FROM="" MODIFIED="2013-05-26 23:54:31 +0100" MODIFIED_BY="Liz Dooley" REVIEW_NO="A059" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2013-05-26 23:54:31 +0100" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2011-06-21 21:10:03 +1000" MODIFIED_BY="[Empty name]">Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis</TITLE>
<CONTACT MODIFIED="2013-05-26 23:54:31 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="4919" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Kameshwar</FIRST_NAME><LAST_NAME>Prasad</LAST_NAME><EMAIL_1>drkameshwarprasad@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>All India Institute of Medical Sciences</ORGANISATION><ADDRESS_1>Ansarinagar</ADDRESS_1><CITY>New Delhi</CITY><ZIP>110029</ZIP><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 11 6518872</PHONE_1><PHONE_2>+91 11 6864851 ext: 3497</PHONE_2><FAX_1>+91 11 6862663</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-05-26 23:54:31 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="4919" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Kameshwar</FIRST_NAME><LAST_NAME>Prasad</LAST_NAME><EMAIL_1>drkameshwarprasad@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>All India Institute of Medical Sciences</ORGANISATION><ADDRESS_1>Ansarinagar</ADDRESS_1><CITY>New Delhi</CITY><ZIP>110029</ZIP><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 11 6518872</PHONE_1><PHONE_2>+91 11 6864851 ext: 3497</PHONE_2><FAX_1>+91 11 6862663</FAX_1></ADDRESS></PERSON><PERSON ID="08F7F05682E26AA201FDBE171BD51A15" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Amit</FIRST_NAME><LAST_NAME>Kumar</LAST_NAME><POSITION>Senior Research Fellow</POSITION><EMAIL_1>amits52003@yahoo.co.in</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>All India Institute of Medical Sciences</ORGANISATION><ADDRESS_1>Ansarinagar</ADDRESS_1><CITY>New Delhi</CITY><ZIP>110029</ZIP><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 9868433728</PHONE_1><FAX_1>+91 11 2658 8641</FAX_1></ADDRESS></PERSON><PERSON ID="16966" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tarun</FIRST_NAME><LAST_NAME>Singhal</LAST_NAME><POSITION>Resident Physician</POSITION><EMAIL_1>t_singhal@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>Yale-New Haven Hospital</ORGANISATION><ADDRESS_1>333 Cedar Street</ADDRESS_1><CITY>New Haven</CITY><ZIP>CT-06511</ZIP><REGION>Connecticut</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 203 804 5131</PHONE_1></ADDRESS></PERSON><PERSON ID="16959" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Praveen Kumar</FIRST_NAME><LAST_NAME>Gupta</LAST_NAME><SUFFIX>MBBS, MS, MCh, FRCS</SUFFIX><POSITION>Consultant Neurosurgeon</POSITION><EMAIL_1>pkguptaram@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Neurosciences</DEPARTMENT><ORGANISATION>Salmaniya Medical Centre</ORGANISATION><ADDRESS_1>PO Box 12, Ministry of Health</ADDRESS_1><CITY>Manama</CITY><COUNTRY CODE="BH">Bahrain</COUNTRY><PHONE_1>+973 17 288 888 extn. 4373</PHONE_1><PHONE_2>+973 391 70807; +973 17 276112</PHONE_2><FAX_1>+973 17 278 382</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-05-30 08:20:32 +1000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="7" MONTH="4" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="4" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="4" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2013-05-27 08:53:02 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2013-05-27 08:53:02 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>We do not think any new trials will appear in the literature that fulfills the inclusion criteria for this review. Current guidelines for choice of antibiotics universally recommend third generation cephalosporin (<U>+ </U>vancomycin) as an empiric therapy in community-acquired bacterial meningitis and has become &#8216;standard of care&#8217;. This is based on the emergence of antibiotic resistance of common aetiologic organisms. Thus, any trial with one arm receiving older (conventional) antibiotics, such as penicillin or chloramphenicol will probably be considered unethical. Hence, we do not think any new trial of these interventions will appear in the literature.</P>
<P>We also conducted a search on &#8216;PubMed&#8217; from March 2006 to May 2013 using keywords  &#8216;meningitis&#8217; AND &#8216;cephalosporin&#8217; OR &#8216;ceftraxone&#8217; OR &#8216;cefotaxime&#8217; OR &#8216;ceftazidime&#8217; OR &#8216;cefmenoxime&#8217; OR &#8216;cefodizime&#8217; OR &#8216;ceftizoxime&#8217; OR &#8216;moxalactam&#8217; OR &#8216;third generation cephalosporin&#8217; AND &#8216;conventional antibiotics&#8217; or &#8216;ampicillin&#8217; OR &#8216;penicillin&#8217; OR &#8216;ampicillin-chloramphenicol&#8217; without any language or publication restrictions. We retrieved 627 hits. After reading the titles we excluded 600 trials and after reading the abstracts we excluded 27 trials. We did not find any new study that fulfilled our inclusion criteria.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-05-27 08:47:54 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-05-27 08:47:54 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="4" YEAR="2011"/>
<DESCRIPTION>
<P>Searches conducted. No new trials were identified for inclusion. One trial was excluded in this update (<LINK REF="STD-Wazib-2008" TYPE="STUDY">Wazib 2008</LINK>). Our conclusions remain unchanged</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-01-13 10:31:30 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-08-15 20:00:54 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="21" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>In this 2007 updated review, a new study from Niger has been added to the review. Overall conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>All India Institute of Medical Sciences, New Delhi</NAME>
<COUNTRY CODE="IN">India</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-08-09 13:43:47 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-07-29 12:07:56 +1000" MODIFIED_BY="[Empty name]">
<TITLE>Newer, third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis</TITLE>
<SUMMARY_BODY MODIFIED="2011-07-29 12:07:56 +1000" MODIFIED_BY="[Empty name]">
<P>Acute bacterial meningitis is a life-threatening illness. Currently the evidence suggests that old and new antibiotics offer the same level of treatment. Bacteria which cause meningitis are often thought to be resistant to conventional (older) antibiotics, and so doctors often prescribe newer antibiotics (called third generation cephalosporins). Commencing treatment early is vitally important and the choice of antibiotic is often made without any knowledge of possible drug resistance. This review examined 19 studies with 1496 participants to see whether there is a difference in effectiveness between conventional and newer antibiotics. This review found no differences. Adverse effects in both approaches were similar, except for diarrhoea, which was more common in the cephalosporin group. Only three studies dealt with adults; the remaining studies recruited participants aged 15 years and younger. Therefore, we believe that the results probably pertain more to children. Conventional and newer antibiotics seem reasonable options for initial, immediate treatment. The choice may depend on availability, affordability and local policies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-08-09 13:40:51 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-08-06 05:45:25 +1000" MODIFIED_BY="[Empty name]">
<P>Antibiotic therapy for suspected acute bacterial meningitis (ABM) needs to be started immediately, even before the results of cerebrospinal fluid (CSF) culture and antibiotic sensitivity are available. Immediate commencement of effective treatment using the intravenous route may reduce death and disability.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-07-30 17:20:57 +1000" MODIFIED_BY="[Empty name]">
<P>The objective is to compare the effectiveness and safety of third generation cephalosporins (ceftriaxone or cefotaxime) with conventional treatment using penicillin or ampicillin-chloramphenicol in patients with community-acquired ABM.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-08-03 15:11:23 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2011, Issue 1), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (January 1966 to March week 4, 2011) and EMBASE (January 1974 to April 2011). We also searched the reference list of review articles and book chapters, and contacted experts for any unpublished trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-08-03 15:13:46 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing third generation cephalosporins (ceftriaxone or cefotaxime) with conventional antibiotics (ampicillin-chloramphenicol combination, or chloramphenicol alone) as empirical therapy for ABM in adults and children.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-04-12 14:05:02 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently applied the study selection criteria, assessed methodological quality and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-08-09 13:40:40 +1000" MODIFIED_BY="[Empty name]">
<P>Nineteen trials that involved 1496 patients were included in the analysis. There was no heterogeneity of results among the studies in any outcome except diarrhoea. There was no statistically significant difference between the groups in the risk of death (risk difference (RD) 0%; 95% confidence interval (CI) -3% to 2%), risk of deafness (RD -4%; 95% CI -9% to 1%) or risk of treatment failure (RD -1%; 95% CI -4% to 2%). However, there were significantly decreased risks of culture positivity of CSF after 10 to 48 hours (RD -6%; 95% CI -11% to 0%) and statistically significant increases in the risk of diarrhoea between the groups (RD 8%; 95% CI 3% to 13%) with the third generation cephalosporins. The risk of neutropaenia and skin rash were not significantly different between the two groups. However, due to increased antibiotic resistance since the 1980s, the finding of this review should be read with caution.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-08-09 13:40:51 +1000" MODIFIED_BY="[Empty name]">
<P>The review shows no clinically important difference between third generation cephalosporins (ceftriaxone or cefotaxime) and conventional antibiotics (ampicillin-chloramphenicol combination, or chloramphenicol alone). Therefore the choice of antibiotic will depend on cost and availability. The antimicrobial resistance pattern against various antibiotics needs to be closely monitored in low- to middle-income countries as well as high-income countries.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-08-09 13:43:17 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-08-03 16:33:31 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-07-29 12:07:50 +1000" MODIFIED_BY="[Empty name]">
<P>Acute bacterial meningitis (ABM) is a major cause of death and disability, especially in low- to middle-income countries. Despite advances in understanding the pathophysiology of meningitis and new brain imaging techniques, the case fatality rate of ABM is still around 10% to 30% and an additional 20% to 50% of cases have only partial recovery with long-term disability.</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-06-28 11:35:54 +1000" MODIFIED_BY="[Empty name]">
<P>One of the major concerns in the treatment of ABM is the emergence of resistant bacterial strains to conventional antibiotics. An increasing number of B-lactamase-producing strains of <I>Haemophilus influenzae</I> (<I>H. influenzae</I>) type b are resistant to ampicillin, and a smaller number of chloramphenicol acetyltransferase-producing strains are resistant to chloramphenicol (<LINK REF="REF-Kaplan-1988b" TYPE="REFERENCE">Kaplan 1988b</LINK>). There have been reports of penicillin resistant meningococci (<LINK REF="REF-Sutcliffe1988" TYPE="REFERENCE">Sutcliffe1988</LINK>) and strains of pneumococci resistant to penicillin have also been reported (<LINK REF="REF-Kaplan-1988b" TYPE="REFERENCE">Kaplan 1988b</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2011-08-03 16:33:06 +1000" MODIFIED_BY="[Empty name]">
<P>Antibiotic therapy for ABM needs to be commenced before the results of cerebrospinal fluid (CSF) culture and sensitivity to antibiotics are available. Empirical therapy should be based on the most common bacterial species that cause the disease, according to the patient's age group or clinical setting and local antibiotic susceptibility patterns of the predominant pathogens. Third generation cephalosporins, including cefotaxime and ceftriaxone, are known to possess broad-spectrum antibacterial activity against the three most common causative agents of ABM: 1. <I>Streptococcus pneumoniae </I>(<I>S. pneumoniae</I>),<I> </I>2. <I>Neisseria meningitidis (N. meningitidis</I>) and 3. <I>H. influenzae</I> type b. Several authors have recommended using third generation cephalosporins as the first-line drugs of choice. However, non-availability of antibiotics is a major issue in low- to middle-income countries. In parts of Africa where meningitis epidemics are common, oily chloramphenicol injections face uncertain production (<LINK REF="STD-Nathan-2005" TYPE="STUDY">Nathan 2005</LINK>). In many low- to middle-income countries, including India, large rural areas have no access to third generation cephalosporins. The lack of access is due to the expense and the fact that the drugs are not readily available. The choice, therefore, lies in using conventional antibiotics or third generation cephalosporins - whichever is obtainable. </P>
</THEORY>
<IMPORTANCE MODIFIED="2011-08-03 16:33:31 +1000" MODIFIED_BY="[Empty name]">
<P>It is not clear whether current evidence supports the equivalence of third generation cephalosporins and conventional antibiotics. This review aimed to determine whether there is any difference in the effectiveness and safety of the third generation cephalosporins cefotaxime and ceftriaxone and conventional antibiotics in the empirical therapy of community-acquired ABM.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of the review was to compare the effectiveness and safety of third generation cephalosporins with penicillin and ampicillin-chloramphenicol or other conventional antibiotic therapies in patients with community-acquired ABM.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-08-03 16:37:24 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-08-03 15:11:51 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-07-29 12:19:29 +1000" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs), irrespective of publication status, in which a third generation cephalosporin was compared to a conventional antibiotic in patients with ABM.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-08-03 15:11:51 +1000" MODIFIED_BY="[Empty name]">
<P>We included patients of any age or sex with community-acquired ABM. The criteria we used for diagnosis of ABM included various combinations of clinical features and CSF composition. Clinical features consisted of fever, headache, vomiting and neck stiffness, with or without altered sensorium. CSF analysis consisted of polymorphonuclear pleocytosis, increased CSF protein and diminished CSF glucose.</P>
<P>We excluded studies containing:</P>
<OL>
<LI>meningitis following lumbar puncture (done for unrelated reasons such as epidural anaesthesia);</LI>
<LI>meningitis associated with head trauma, CSF leak, neurosurgery, known para-meningeal focus of infection (defined as infection at sites in close proximity to the meninges, namely otitis media, cranial osteomyelitis or brain abscess); or</LI>
<LI>known immunosuppression (defined as a condition associated with suppressed immune response). For example, intake of immunosuppressive drugs or presence of diseases like malignancy, HIV positivity or systemic lupus erythematosus etc.).</LI>
</OL>
<P>We excluded studies if their title or abstract explicitly mentioned that the focus of the studies was on meningitis associated with one of these conditions listed above.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-07-29 12:38:35 +1000" MODIFIED_BY="[Empty name]">
<P>The interventions were any third generation cephalosporin compared with conventional antibiotic treatment. The third generation cephalosporins we considered were:</P>
<OL>
<LI>cefotaxime; and</LI>
<LI>ceftriaxone.</LI>
</OL>
<P>The conventional treatment may include:</P>
<OL>
<LI>penicillin alone;</LI>
<LI>ampicillin-chloramphenicol combination;</LI>
<LI>penicillin-chloramphenicol combination; and</LI>
<LI>chloramphenicol alone, including single oily injections of chloramphenicol.</LI>
</OL>
<P>Considering the seriousness of the disease, the preferred route of administration of the interventions was intravenous. Our protocol specified this as a preferred route in the studies to be included. However, we also considered for inclusion, trials with other or multiple routes (for example, intravenous followed by oral).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-07-30 17:28:09 +1000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-07-30 17:28:09 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Deaths from any cause, in hospital or during a follow-up period.</LI>
<LI>Severe deafness, defined as interfering (or likely to interfere) with usual activity.</LI>
<LI>Other disabling sequelae, defined as any sequelae at the end of the follow-up period which caused dependence in any activity of daily living (for example, walking, toileting, bathing, dressing and eating) or caused inability to carry out previous work.</LI>
<LI>Treatment failure, defined as presence of one or more of the primary outcomes (for example, death, disabling sequelae, or severe deafness (defined above)) at the end of follow-up.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-07-29 12:44:42 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Side effects of drugs, for example, diarrhoea, agranulocytosis or skin rash.</LI>
<LI>Culture positivity of CSF for the causative bacteria, after 10 to 48 hours.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-07-30 17:50:44 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2011-07-30 17:50:44 +1000" MODIFIED_BY="[Empty name]">
<P>For this review update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>2011, Issue 1), part of www.thecochranelibrary.com (accessed 7 April 2011), which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (March 2007 to March week 4, 2011); and EMBASE (March 2007 to April 2011) (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). We also searched the reference list of review articles and book chapters, and contacted experts for any unpublished trials. We imposed no language or publication restrictions. </P>
<P>We searched MEDLINE and CENTRAL using the keywords and MeSH terms in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. We combined the MEDLINE terms with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). We searched EMBASE using an amended version of this strategy (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). See <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> for details of previous search.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-06-28 11:49:13 +1000" MODIFIED_BY="[Empty name]">
<P>We contacted content experts for any unpublished trials. To date, pharmaceutical companies manufacturing third generation cephalosporins have not responded to requests for unpublished trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-08-03 16:37:24 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-07-29 13:05:33 +1000" MODIFIED_BY="[Empty name]">
<P>Three review authors (AK, TS, PKG) independently selected trials for inclusion in the review. We resolved disagreements by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-08-03 16:34:16 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (AK, KP) independently extracted and cross-checked the outcome data. We resolved disagreements by discussion.<BR/>
</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-07-30 14:19:34 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (AK, KP) independently assessed the risk of bias of the included trials according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>) based on the following six domains with the rating of low risk of bias, high risk of bias and uncertain risk of bias.</P>
<OL>
<LI>Random sequence generation.</LI>
<LI>Allocation concealment.</LI>
<LI>Blinding.</LI>
<LI>Incomplete outcome data.</LI>
<LI>Selective reporting.</LI>
<LI>Other bias.</LI>
</OL>
<P>We did not consider blinding to be a major issue as the included outcomes can be measured objectively. Other criteria included the prognostic balance between the two treatment arms and the completeness and length of follow-up.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-07-29 13:47:38 +1000" MODIFIED_BY="[Empty name]">
<P>We intended to use risk ratio (RR) and risk difference (RD) for calculating proportional and absolute risk reductions, respectively. However, in many studies there were no deaths (or other outcomes) in any group and the only estimate which we could use to include all such studies in the analysis, was RD. Therefore, we used RD to summarise the results. Use of RR or odds ratio (OR) would have excluded many studies from the analysis.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-07-29 13:48:49 +1000" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was the individual patients included in the study. We did not find any cross-over or cluster-randomised trials on this topic.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-07-29 13:50:09 +1000" MODIFIED_BY="[Empty name]">
<P>We recorded the number of randomised and analysed studies to determine if authors conducted an intention-to-treat (ITT) analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-08-03 16:37:24 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity in all analyses with an I<SUP>2 </SUP>statistic value of<SUP> </SUP>&#8805; 50% taken to indicate statistical heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-04-12 14:18:20 +1000" MODIFIED_BY="[Empty name]">
<P>We conducted a visual inspection of the funnel plot of the studies for any obvious asymmetry that could indicate publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-07-29 14:16:11 +1000" MODIFIED_BY="[Empty name]">
<P>We analysed the data using Review Manager 5.1 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). We used the Dersimonian and Laird method to calculate the summary estimate (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). We calculated the summary estimates using the fixed-effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-07-29 14:21:43 +1000" MODIFIED_BY="[Empty name]">
<P>We conducted subgroup analyses based on the causative organism for <I>H. influenzae, S. pneumoniae </I>and<I> N. meningitidis</I>, as specified in the protocol. We also examined the outcomes of death, deafness and treatment failure for high income and low- to middle-income countries separately. The definition of income categories was according to gross national income (GNI) per capita (based on World Bank criteria) as follows: low-income countries in which the GNI per capita was $745 or less; in lower middle-income countries, $746 to $2,975; in upper middle-income countries, $2976 to $9205; and in high-income countries, $9206 or more. For our analysis, we collapsed the low- and both middle-income categories into one, termed as low- to middle-income countries (GNI $9205 or less). An income-based classification of countries where studies were done is represented in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.<BR/>
</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-07-29 14:40:49 +1000" MODIFIED_BY="[Empty name]">
<P>We carried out a sensitivity analysis for each outcome as well as on the composite outcome of treatment failure. We defined treatment failure as the presence of one or more of the primary outcomes, that is death, disabling sequelae or severe deafness (defined above under <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>) at the end of follow-up. Combining the results, we included all studies in our primary analysis. Next, as intended in our protocol, we set out to examine studies from high-income and low- to middle-income countries separately as a secondary analysis. We conducted both overall and organism-specific analyses.</P>
<P>There may be a view that the assumption of a fixed-effect model is not correct because the studies from low- to middle-income and high-income countries may not be measuring the same underlying effects, even though the test for homogeneity was statistically non-significant. To examine whether the results were sensitive to this assumption, we examined the effect using a random-effects model. We did not find any important differences in the results.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-08-09 13:41:12 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-07-30 11:33:54 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2011-07-30 11:25:24 +1000" MODIFIED_BY="[Empty name]">
<P>In this 2011 update we retrieved 104 records when searching the electronic databases. We excluded one new trial (<LINK REF="STD-Wazib-2008" TYPE="STUDY">Wazib 2008</LINK>).</P>
<P>Death was reported clearly in all studies. Six studies had no deaths in any group. Deaths were more common in studies in low- to middle-income countries. In studies from high-income countries, there were seven deaths in each arm: among 254 patients in cephalosporins and 256 patients in conventional arms; whereas there were 37 deaths among 409 patients in the cephalosporin group and 36 deaths among 382 patients in the conventional group in low- to middle-income countries. The reporting of outcomes other than death was inconsistent across studies. Deafness was classified as mild, moderate and severe in some, while not in others. It was difficult to determine whether the deafness reported in the studies interfered with usual activities, the outcome we planned to analyse. We took moderate hearing loss, even in one ear, as interfering with usual activities. For disability (other than deafness) there was no consistency in reporting. Some studies reported incidence of various neurological sequelae, but the number of participants involved was not clear. There were participants with more than one sequela and therefore, we could not extract the analysable data on disability.</P>
<P>Details of each study are given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-07-30 11:30:28 +1000" MODIFIED_BY="[Empty name]">
<P>Nineteen trials with 1496 participants met the inclusion criteria (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table). The empirical experimental treatment was ceftriaxone in 16, cefotaxime in two and ceftazidime in one trial. The empirical control treatment was ampicillin plus chloramphenicol in nine, ampicillin plus chloramphenicol plus gentamicin in three, benzylpenicillin plus chloramphenicol in two, ampicillin alone in two, benzylpenicillin alone in two, and oily injection of chloramphenicol in one trial.</P>
<P>The minimum age was one month (post-neonatal), except in two studies (<LINK REF="STD-Congeni-1984" TYPE="STUDY">Congeni 1984</LINK>; <LINK REF="STD-Steele-1983" TYPE="STUDY">Steele 1983</LINK>) that had a minimum age of seven days and 14 days, respectively. Only four studies included adults, of which two were restricted to participants older than 15 years of age. Ten studies were from low- to middle-income countries and nine from high-income countries.</P>
<P>Thirteen studies continued the same antibiotic as the empirical therapy throughout the course of treatment, but in four studies the culture report determined the antibiotic regimen following the initial empiric therapy; but changes (only in the control group) were within the conventional regimens. In one study (<LINK REF="STD-Peltola-1989" TYPE="STUDY">Peltola 1989</LINK>) two participants in the chloramphenicol group had the addition of cefotaxime; one participant in the cefotaxime group had the addition of ampicillin; and four participants in the ceftriaxone group had the addition of chloramphenicol, ampicillin or penicillin. Thus, there has been little contamination (crossover) between the experimental and control groups. One study (<LINK REF="STD-Nathan-2005" TYPE="STUDY">Nathan 2005</LINK>) reported a single injection of ceftriaxone (100 mg/kg to a maximum of 4 g in one intramuscular dose) or oily chloramphenicol (100 mg/kg to a maximum of 3 g in one intramuscular dose).</P>
<P>The follow-up period was confined to 72 hours in one study, hospital stay in two studies, one to two weeks in four, more than one month in eight, and not mentioned in four studies. Five studies had a follow-up of three months or more. Peltola (<LINK REF="STD-Peltola-1989" TYPE="STUDY">Peltola 1989</LINK>) had a follow-up of 12 months.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-07-30 11:33:54 +1000" MODIFIED_BY="[Empty name]">
<P>The <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table gives reasons for exclusion. Briefly, the studies did not qualify because two were only pharmacokinetic studies, five were non-RCTs, four were narrative review articles, two had ineligible participants, 12 did not have the desired interventions (for example, six did not have an arm with third generation cephalosporins) and one was a duplicate publication.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-08-04 07:00:01 +1000" MODIFIED_BY="[Empty name]">
<P>We considered concealment of randomisation, blinding, completeness of follow-up and ITT analysis.</P>
<ALLOCATION MODIFIED="2011-07-30 11:41:38 +1000" MODIFIED_BY="[Empty name]">
<P>None of the studies described in detail the method to conceal the randomisation process. One study (<LINK REF="STD-Nathan-2005" TYPE="STUDY">Nathan 2005</LINK>) described use of a computer for sequence generation and sealed envelopes for treatment allocation. One study (<LINK REF="STD-Peltola-1989" TYPE="STUDY">Peltola 1989</LINK>) mentioned using the telephone to randomly allocate the participants. The recruiting person assessed eligible participants, telephoned the person holding the randomisation sequence for allocation, registered the participant and secured the allocation. Probably all cases were randomised by telephone, and thus the process was adequately concealed. Concealment might not be a major issue if consecutive participants eligible for inclusion in the studies were randomised, but it was unclear whether this was indeed the case in the studies.</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-07-30 11:42:16 +1000" MODIFIED_BY="[Empty name]">
<P>No study had drug packs similar in appearance for the treatment and control arms. Blinding was mentioned in only one study and the term used was "single-blinded". It is not clear who was blinded and how, but most likely the participants were blinded. Blinding may not be relevant for measuring the fatal outcomes, and probably deafness by audiometry, but measurement of other outcomes may be influenced by the lack of blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-07-30 11:43:24 +1000" MODIFIED_BY="[Empty name]">
<P>No study clearly stated that there were no losses to follow-up. This raises concern whether the losses to follow-up were excluded from data analysis. However, for mortality this is unlikely to be a major issue because nearly all deaths in this disease occur in hospital.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-05-30 08:35:35 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed the selective reporting of data by comparing the outcomes listed in the methods section of the trials and the outcomes listed in the results.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2011-08-04 07:00:01 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed other sources that could potentially bias the results. Possible sources included design-specific risk of bias, early stopping, baseline imbalance and inappropriate administration of a co-intervention.</P>
<SUBSECTION>
<HEADING LEVEL="4">Completeness of follow-up</HEADING>
<P>No study clearly stated that there were no losses to follow-up, but the number analysed and randomised were the same in 15 studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">ITT analysis</HEADING>
<P>Only one study (<LINK REF="STD-Nathan-2005" TYPE="STUDY">Nathan 2005</LINK>) clearly mentioned that the ITT principle was used in the analysis. Most studies excluded participants from analysis if they turned out to have aseptic meningitis. If this was done irrespective of and without knowledge of the outcome, it may not create a significant bias. However, the studies do not report this clearly.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-08-09 13:41:12 +1000" MODIFIED_BY="[Empty name]">
<P>Initially we considered 52 studies. Two review authors (KP, TS) applied the inclusion and exclusion criteria. The observed agreement for inclusion and exclusion was 88% and the kappa coefficient was 0.76, indicating an excellent level of chance-corrected agreement. We resolved disagreements through discussion. Nineteen studies were included and 33 excluded.</P>
<P>The agreement between the two review authors (TS, TJ) on methodological quality of the studies was also high (observed agreement 89% for adequate description of method randomisation and 100% for blinding); the corresponding kappa coefficient for randomisation was 0.72 and weighted kappa coefficient for blinding was 1.0. The main observation with regards to the quality of the studies was that this was not adequately assessable from the reports. The <LINK REF="STD-Peltola-1989" TYPE="STUDY">Peltola 1989</LINK> study did seem to fulfil most of the methodological criteria. However, the other 18 studies were also given the benefit of the doubt and included in the analysis.</P>
<P>We included 19 trials, involving 1496 participants in the analysis. The ages ranged from one week to 59 years, but only four studies included adults and only two studies were restricted to adults. The duration of illness before the start of treatment was less than two days in two studies; two to four days in seven; more than four days in one; and not mentioned in eight studies. There was no heterogeneity of results among the studies in any outcome except diarrhoea (see below). The route of administration of antibiotics was parenteral in 17 studies (intravenous in 15 and intramuscular in two studies). The remaining two studies started with the intravenous route and changed over to oral (in the conventional antibiotic group) after the participants improved.</P>
<P>Most of the included studies did not mention the rates of antimicrobial resistance of the isolates. We found only two studies giving this information. <LINK REF="STD-Jacobs-1985" TYPE="STUDY">Jacobs 1985</LINK> reported 29 isolates of <I>H. influenzae</I>, of which 34% were resistant to ampicillin, none were resistant to chloramphenicol or cefotaxime; eight isolates of <I>S. pneumoniae</I>, of which one was "relatively resistant" to penicillin (MIC 0.8 mcg/ml); and eight isolates of <I>N. meningitidis</I>, of which all were sensitive to cefotaxime. <LINK REF="STD-Aronoff-1984" TYPE="STUDY">Aronoff 1984</LINK> reported two isolates of <I>N. meningitidis</I>; both were susceptible to ampicillin, chloramphenicol and ceftriaxone. He also reported one isolate of <I>S. pneumoniae</I>, which was susceptible to ceftriaxone. Overall, there was limited information on sensitivity of the isolates.</P>
<SUBSECTION>
<HEADING LEVEL="3">Death</HEADING>
<P>The total number of deaths was 52 (out of 750) in the cephalosporin group and 50 (out of 746) in the conventional antibiotic group. There was no statistically significant difference in the risk of death between the groups (RD 0%; 95% CI -3% to 2%). However, the 95% CI indicated that a small difference, of 3% less or 2% more mortality in the cephalosporin group compared to the conventional antibiotic group, cannot be ruled out with 95% certainty.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Deafness</HEADING>
<P>This was present in 21 (out of 247) in the cephalosporin group and 30 (out of 254) in the conventional antibiotic group. There was no statistically significant difference in the risk of deafness between the groups (RD -4%; 95% CI -9% to 1%). This result should be read with caution because this outcome is lower in hierarchy than mortality. In a disease with mortality, a treatment may reduce incidence of deafness by allowing (or causing) more deaths in that arm, thus leaving less people to report deafness. For this reason, death and deafness need to be combined as one outcome, 'treatment failure' (see next outcome).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Treatment failure</HEADING>
<P>We considered treatment failure as the presence of either death or deafness (other disabling sequelae were not reported clearly enough to be included under this outcome). This analysis was done for the reason given above and to increase power for the analysis. The total number of treatment failures was 63 (out of 750) in the cephalosporin group and 65 (out of 746) in the conventional antibiotic group. There was no statistically significant difference in the risk of treatment failure between the groups (RD -1%; 95% CI -4% to 2%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Culture positivity of CSF after 10 to 48 hours</HEADING>
<P>Culture positivity of CSF after 10 to 48 hours was reported in 12 studies. It was seen in a total 14 (out of 228) in the cephalosporin group and 25 (out of 214) in the conventional antibiotic group. There was a statistically significant difference in the risk of culture positivity of CSF after 10 to 48 hours between the groups (RD -6%; 95% CI -11% to 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Neutropaenia</HEADING>
<P>Neutropaenia was reported in 10 trials. The total number with neutropaenia was 7 (out of 240) in the cephalosporin group and 12 (out of 217) in the conventional antibiotic group. There was no statistically significant difference in the risk of neutropaenia between the groups (RD -3%; 95% CI -7% to 2%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Diarrhoea</HEADING>
<P>Diarrhoea was reported in 10 trials. The total number of diarrhoeal incidents was 76 (out of 369) in the cephalosporin group and 45 (out of 361) in the conventional antibiotic group. There was a statistically significant difference in the risk of diarrhoea between the groups (RD 8%; 95% CI 3% to 13%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Skin rash</HEADING>
<P>Skin rash was reported in seven trials. The total number of participants with skin rash was 1 (out of 249) in the cephalosporin group and 4 (out of 219) in the conventional group. There was no statistically significant difference in the risk of skin rash between the groups (RD -1%; 95% CI -4% to 2%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>The results of analysis according to the causative organism also did not reveal any difference between the two regimens, though the data were sparse. The organism-wise data could be extracted for death only. The RD for <I>H. influenzae</I> was 1% (95% CI -5% to 6%); for <I>S. pneumoniae </I>RD -2% (95% CI -18% to 14%); and for <I>N. meningitis </I>RD 0% (95% CI -5% to 4%). The data for <I>S. pneumoniae</I> were particularly sparse with wide CIs and therefore, need to be read with caution.</P>
<P>Separate analyses for low- to middle-income and high-income countries yielded very similar results. Again, subgrouping of the studies, as expected, reduced the power of the analysis to exclude clinically important differences. An income-based classification of countries where studies were conducted is summarised in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.<BR/>
</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-08-09 13:43:17 +1000" MODIFIED_BY="[Empty name]">
<P>We have conducted a systematic review using Cochrane methodologies to address the question of whether there is any difference in the effectiveness and safety between third generation cephalosporins and conventional antibiotic treatments in patients with community-acquired ABM.</P>
<SUMMARY_OF_RESULTS MODIFIED="2011-07-30 12:22:35 +1000" MODIFIED_BY="[Empty name]">
<P>Our results essentially show no important difference between the cephalosporins and conventional antibiotics groups in any of the outcomes, except for culture positivity at 10 to 48 hours and diarrhoea. However, absence of evidence of difference may not be taken as evidence of absence of a difference. A small difference between the two groups in death, deafness or treatment failure cannot be ruled out, but we doubt if the small difference would be considered clinically important by most physicians.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-08-09 13:42:17 +1000" MODIFIED_BY="[Empty name]">
<P>Agreement between the review authors in the selection of studies, quality assessment and data extraction was high. Two review authors (KP, AK) resolved all disagreements through discussion or by referral to a third review author (PKG). This provides confidence in the control of bias in the reviewing process. The main problem we faced during data extraction was high variability in the way disability was defined or assessed. Multiple sequelae in the same person were counted separately, thus the number of patients with one or more disabilities could not be extracted. This rendered disability data non-analysable. However, deafness was recorded consistently, though not in a uniform fashion. We feel that there is a need to standardise the outcome definitions and assessment methods, particularly for non-fatal outcomes in meningitis studies.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-08-06 04:53:40 +1000" MODIFIED_BY="[Empty name]">
<P>We included 19 studies in our meta-analysis; there may be some unpublished studies. The inclusion of such studies may have enhanced the power of analysis but there is no reason to believe that they would have significantly different results. The funnel plot (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) does not reveal any asymmetry, indicating that publication bias is unlikely to be significant. Many studies included in the analysis suggest uncertainty regarding their quality. How much of this is a reflection of the style of reporting or editorial restrictions in the form and length of papers, and how much is due to the actual methodological quality, is difficult to say. But the striking similarity in results across the different studies suggests that the conclusions are robust.</P>
<P>There are only two statistically significant differences between the two groups in this review. Culture positivity after 10 to 48 hours is reduced with the use of third generation cephalosporins, indicating rapid sterilisation of the CSF with this group of drugs. However, only two studies (<LINK REF="STD-Congeni-1984" TYPE="STUDY">Congeni 1984</LINK>; <LINK REF="STD-Odio-1986" TYPE="STUDY">Odio 1986</LINK>) are driving the statistical significance, the rest show practically no difference in sterilisation of CSF. Moreover, this is an intermediate outcome. If the final outcome is no different, the two antibiotic regimens may be considered equally effective. To show that the two regimens are not different requires adequate power (this point is discussed below under 'limitations'). Diarrhoea was more frequent in the cephalosporins group. However, no study reported that this was uncontrollable or associated with <I>Clostridium difficile</I> (<I>C. difficile</I>), colitis or septicaemia. Therefore, this is unlikely to determine the choice of antibiotics. It may be worth mentioning that some evidence is emerging to suggest that antibiotic-associated diarrhoea can be prevented with the use of probiotics (<LINK REF="REF-Johnston-2007" TYPE="REFERENCE">Johnston 2007</LINK>; <LINK REF="REF-Pillai-2008" TYPE="REFERENCE">Pillai 2008</LINK>). Whether or not this applies to meningitis patients being treated with ceftriaxone and cefotaxime is a topic worthy of research.</P>
<P>The data suggest that third generation cephalosporins and the combination of ampicillin-chloramphenicol or chloramphenicol alone can be used as alternative empirical therapies for ABM, but this may not hold true as bacteria increasingly develop resistance to ampicillin and chloramphenicol. There is substantial evidence to suggest that an increasing proportion of <I>H. influenzae</I> and <I>S. pneumoniae</I> isolated from meningitis cases are resistant to ampicillin and chloramphenicol. This suggests that third generation cephalosporins should always be the first choice for empirical therapy for meningitis in the post-neonatal period. The generalisability of the resistance pattern (studied mostly in urban centres) to rural and remote districts of low- to middle-income countries is questionable. Non-availability of these antibiotics and infrequent usage may limit the development of such resistance in remote and rural areas. Also, what if third generation cephalosporins are not available or affordable? This situation is real in many parts of low- to middle-income countries. Despite all efforts by national and international agencies, the situation is unlikely to be resolved over the next few decades. Practitioners may have the option of using conventional antibiotics or no antibiotics. They run the risk of interpreting the literature that conventional antibiotics are as useless as no antibiotic at all. We think our review provides support for continued use of ampicillin-chloramphenicol in such situations. On the other hand, in Africa there is uncertainty about continued production of oily chloramphenicol injections, a commonly used drug during epidemics of meningitis (<LINK REF="STD-Nathan-2005" TYPE="STUDY">Nathan 2005</LINK>). In cases of non-availability of this drug, a single intramuscular injection of ceftriaxone with close follow up is an alternative.</P>
<P>The study by Peltola (<LINK REF="STD-Peltola-1989" TYPE="STUDY">Peltola 1989</LINK>) probably deserves special mention. This is the only study that allowed comparison between ceftriaxone, cefotaxime, ampicillin-chloramphenicol, and chloramphenicol separately. It had the best methodological quality and longest follow up. Its conclusions clearly show that intravenous chloramphenicol alone should never be used, though this may not apply to intramuscular injections of oily chloramphenicol (the study by <LINK REF="STD-Nathan-2005" TYPE="STUDY">Nathan 2005</LINK> shows similar efficacy between intramuscular injection of oily chloramphenicol and ceftriaxone). Also, that there is little to chose between ceftriaxone, cefotaxime and ampicillin on the basis of efficacy. But most of the data is on the combination of ampicillin and chloramphenicol. In addition, many strains resistant to ampicillin are sensitive to chloramphenicol, and vice-versa. Hence the conventional regimen, whenever used, should consist of the ampicillin-chloramphenicol combination, to which the resistance prevalence in low- to middle-income countries is below 10% (<LINK REF="REF-Reis-2002" TYPE="REFERENCE">Reis 2002</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Antibacterial resistance and impact on outcome</HEADING>
<P>There are several papers reporting the increasing trend in the proportion of <I>H. influenzae</I>, <I>S. pneumoniae</I> and <I>N. meningitidis</I> showing resistance to penicillin and chloramphenicol (<LINK REF="REF-Enting-1996" TYPE="REFERENCE">Enting 1996</LINK>; <LINK REF="REF-Mwangi-2002" TYPE="REFERENCE">Mwangi 2002</LINK>; <LINK REF="REF-Tristram-2007" TYPE="REFERENCE">Tristram 2007</LINK>; <LINK REF="REF-Wasfy-2005" TYPE="REFERENCE">Wasfy 2005</LINK>). Thus, use of conventional antibiotics may be associated with higher mortality and morbidity. In fact, <I>H. influenzae</I> and <I>S. pneumoniae </I>have even developed resistance to cephalosporins. This has prompted many experts to advocate the use of combination vancomycin and third generation cephalosporins as the empiric treatment for bacterial meningitis. However, in cases where the isolates turn out to be sensitive to conventional antibiotics, our review indicates that the outcome with third generation cephalosporins and conventional antibiotics is likely to be the same.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Limitations of the review</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Power</HEADING>
<P>This review did not find any difference between the two antibiotic regimens. However, we have to assess the risk of fallacy: "absence of evidence of difference is not evidence of absence of difference''. This fallacy confronts any result or conclusion favouring equivalence. The power necessary to show equivalence theoretically requires infinite sample sizes. In other words, no sample size is large enough to show statistical equivalence. Clinicians will accept two interventions as reasonably equivalent if the 95% CI rules out a clinically important difference, implying that the review had sufficient power to permit clinical equivalence. Here there is room for difference of opinion. What is acceptable to one clinician may not be so for another. The 95% CI of the summary RD for death and severe deafness, in our opinion, excludes any important difference, but a contrary opinion may also be reasonable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Unclear concealment</HEADING>
<P>Usually, a lack of clear concealment is associated with bias towards showing a difference between two arms, which is not the case in this review. However, if the general impression has been that third generation cephalosporins would be a better choice than conventional therapy, then unclear concealment may have led to a tendency to treating the most severely ill patients with third generation cephalosporins. Following this example, unclear concealment could result in a bias towards no difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selection bias</HEADING>
<P>The results probably apply only to children, because there were only three studies with adults; all the remaining studies had participants younger than 15 years old. Also, the mortality observed in these studies (3% in high income countries and 13% in low- to middle-income countries) is low compared to reports in some case series (10% to 30%). This raises concerns about whether the study sample is representative of meningitis cases. If less serious patients are over represented in the studies, the findings may not generalise to all meningitis cases. Any difference between treatments is more likely to be detectable in seriously ill patients and thus the studies might have underestimated any difference which might exist.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Time of the studies</HEADING>
<P>All the studies except for three were conducted in the 1980s. The results might be due to less prevalence of resistance to conventional antibiotics at that time. The same results may not apply now. It should be stressed that the recent studies mainly treated meningococcal meningitis and so the relevance of this review in 2007 may be questioned. When so much has been written about increasing resistance to ampicillin, chloramphenicol, and even to ceftriaxone and cefotaxime, what purpose does this review serve? We believe the review does serve a purpose. In some low- to middle-income countries, one of the cephalosporins or conventional antibiotics may not be available or affordable. In Africa, there is uncertainty about continued production of oily chloramphenicol, whereas ceftriaxone injections may be available. We know that most people in other low- to middle-income countries, where both groups of antibiotics are available, have to spend out-of-pocket for all treatments. We also know that poor people cannot afford to buy third generation cephalosporins. In many hospitals in low- to middle-income countries, ampicillin and chloramphenicol may be freely available but not ceftriaxone or cefotaxime. We do not believe that the situation will change for several years. This review provides support for combination ampicillin-chloramphenicol as an alternative to third generation cephalosporins when the latter is not available or affordable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lack of ITT analysis</HEADING>
<P>The included studies (except <LINK REF="STD-Nathan-2005" TYPE="STUDY">Nathan 2005</LINK>) did not use an ITT analysis. This may have introduced a different degree of bias in the results of different studies. Usually the resulting bias in studies overestimates difference between the two arms. As the final results do not show any difference, this may not be a matter of great concern.</P>
<P>Overall risk of bias is represented in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-08-09 13:43:17 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (KP, AK) independently assessed trial selection, quality assessment and data extraction, as recommended in the <I>Cochrane</I> <I>Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). We did this in order to avoid bias in the reviewing process. Our searches were reasonably comprehensive and we believe they identified all relevant studies. The funnel plot did not reveal any asymmetry which indicates that publication bias was unlikely.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-07-30 14:23:51 +1000" MODIFIED_BY="[Empty name]">
<P>We are not aware of any other systematic review on this topic, but recent recommendations for the treatment of acute pyogenic meningitis favour third generation cephalosporins, thus indicating that those countries where conventional antibiotics are becoming unavailable (for example some African countries), can switch over to using third generation cephalosporin.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-04-12 14:13:45 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE>
<P>Although the review shows no clinically important difference between ceftriaxone and cefotaxime versus conventional antibiotics, the studies were conducted two decades ago and may not apply to current routine practice. Whenever one of the third generation cephalosporins or conventional antibiotics are not available or affordable, the other can be used as an alternative to start initial empirical treatment in ABM. The subsequent course of action may depend on the culture and sensitivity report and the response of the patients to such therapy. However, if intravenous chloramphenicol is used, it should be used in combination with ampicillin.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-04-12 14:13:45 +1000" MODIFIED_BY="[Empty name]">
<P>Studies are needed to evaluate whether newer recommended regimens are superior to those already in practice in areas showing increasing prevalence of resistance to the antibiotics in use. For example, whether vancomycin plus ceftriaxone is better than ceftriaxone alone. The antimicrobial resistance pattern against various antibiotics needs to be determined in rural and remote areas of low- to middle-income as well as in high income countries. This would help to determine the generalisability of changing recommendations due to increasing prevalence of antibiotic resistance observed in urban areas and high income countries.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-07-30 14:25:56 +1000" MODIFIED_BY="[Empty name]">
<P>We acknowledge the infrastructure support provided by the All India Institute of Medical Sciences, New Delhi; the College of Medicine &amp; Medical Sciences; and The Arabian Gulf University, Bahrain. The review authors gratefully acknowledge Dr Mark Coulthard's contribution in developing the protocol and finding the studies; and Dr Nitin Jain for his contribution in the first publication of the review. Finally, we wish to thank the following people for commenting on the updated draft review: Liz Dooley, Sarah Thorning, Alison Thomas, Mette Nørgaard, Xavier Sáez-Llorens, Terry Neeman and Diederik van de Beek.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-08-09 13:43:47 +1000" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-08-09 13:43:39 +1000" MODIFIED_BY="[Empty name]">
<P>Kameshwar Prasad (KP) conceptualised the review, developed and wrote the protocol, contributed to the selection of the studies, extraction of data, entry of data and wrote the final draft of the review. He also conducted the inter-observer agreement analysis and wrote the update of this review.</P>
<P>Amit Kumar (AK) and Tarun Singhal (TS) contributed to the selection of studies, extraction of data, entry of data and review of the final draft. AK and TS entered the data for this update.<BR/>PK Gupta (PKG) contributed to entry of data, prepared tables for agreement analysis and provided valuable comments on the final draft of the review. He participated in the selection of new studies during the update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-08-09 13:49:12 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-07-29 16:07:47 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-07-29 16:07:47 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aronoff-1984" MODIFIED="2011-07-29 15:44:08 +1000" MODIFIED_BY="[Empty name]" NAME="Aronoff 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-07-29 15:44:08 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aronoff SC, Reed MD, O'Brien CA, Blumer JL</AU>
<TI>Comparison of the efficacy and safety of ceftriaxone to ampicillin-chloramphenicol in the treatment of childhood meningitis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1984</YR>
<VL>13</VL>
<NO>2</NO>
<PG>143-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barson-1985" MODIFIED="2011-07-29 15:45:04 +1000" MODIFIED_BY="[Empty name]" NAME="Barson 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-07-29 15:45:04 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barson WJ, Miller MA, Brady MT, Powell DA</AU>
<TI>Prospective comparative trial of ceftriaxone vs conventional therapy for treatment of bacterial meningitis in children</TI>
<SO>Pediatrics Infectious Diseases Journal</SO>
<YR>1985</YR>
<VL>4</VL>
<NO>4</NO>
<PG>362-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bryan-1985" MODIFIED="2011-07-29 15:46:47 +1000" MODIFIED_BY="[Empty name]" NAME="Bryan 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-07-29 15:46:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bryan JP, Rocha H, da Silva HR, Taveres A, Sande MA, Scheld WM</AU>
<TI>Comparison of ceftriaxone and ampicillin plus chloramphenicol for the therapy of acute bacterial meningitis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1985</YR>
<VL>28</VL>
<NO>3</NO>
<PG>361-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Congeni-1984" MODIFIED="2011-07-29 15:49:01 +1000" MODIFIED_BY="[Empty name]" NAME="Congeni 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-07-29 15:49:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Congeni BL</AU>
<TI>Comparison of cefotaxime and traditional therapy of bacterial meningitis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1984</YR>
<VL>25</VL>
<NO>1</NO>
<PG>40-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Del-Rio-1983" MODIFIED="2011-07-29 15:50:45 +1000" MODIFIED_BY="[Empty name]" NAME="Del Rio 1983" YEAR="1983">
<REFERENCE MODIFIED="2011-07-29 15:49:55 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Rio MA, Chrane D, Shelton S, McCraken GH Jr, Nelson JD</AU>
<TI>Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis</TI>
<SO>Lancet</SO>
<YR>1983</YR>
<VL>1</VL>
<NO>8336</NO>
<PG>1241-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Filali-1993" MODIFIED="2011-07-29 15:56:52 +1000" MODIFIED_BY="[Empty name]" NAME="Filali 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-07-29 15:56:52 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El Filali KM, Noun M, Chakib A, Zahraoui M, Himmich H</AU>
<TI>Ceftriaxone versus Penicillin G in the short term treatment of meningococcal meningitis in adults</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1993</YR>
<VL>12</VL>
<NO>10</NO>
<PG>766-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Girgis-1987" NAME="Girgis 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Girgis NI, Abu El-Ella AH, Farid Z, Woody JN, Lissner C</AU>
<TI>Ceftriaxone compared with a combination of ampicillin and chloramphenicol in the treatment of bacterial meningitis in adults</TI>
<SO>Drugs in Experimental and Clinical Research</SO>
<YR>1987</YR>
<VL>XIII</VL>
<NO>8</NO>
<PG>497-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Girgis-1988" NAME="Girgis 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Girgis NI, Abu El-Ella AH, Farid Z, Haberberger RL, Woody JN</AU>
<TI>Ceftriaxone alone compared to ampicillin and chloramphenicol in the treatment of bacterial meningitis</TI>
<SO>Chemotherapy</SO>
<YR>1988</YR>
<VL>34</VL>
<NO>Suppl 1</NO>
<PG>16-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haffejee-1988" MODIFIED="2011-07-29 15:59:14 +1000" MODIFIED_BY="[Empty name]" NAME="Haffejee 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-07-29 15:59:14 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haffejee IE</AU>
<TI>Cefotaxime versus penicillin-chloramphenicol in purulent meningitis: a controlled single-blind clinical trial</TI>
<SO>Annals of Tropical Pediatrics</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>4</NO>
<PG>225-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs-1985" MODIFIED="2011-07-29 15:59:57 +1000" MODIFIED_BY="[Empty name]" NAME="Jacobs 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-07-29 15:59:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs RF, Wells TG, Steele RW, Yamauchi T</AU>
<TI>A prospective randomized comparison of cefotaxime vs ampicillin and chloramphenicol for bacterial meningitis in children</TI>
<SO>Journal of Pediatrics</SO>
<YR>1985</YR>
<VL>107</VL>
<NO>1</NO>
<PG>129-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Narciso-1983" NAME="Narciso 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Narciso P, De Mori P, Giannuzzi R, Tocci G, Visco G</AU>
<TI>Ceftriaxone versus ampicillin therapy for purulent meningitis in adults</TI>
<SO>Drugs in Experimental and Clinical Research</SO>
<YR>1983</YR>
<VL>IX</VL>
<NO>10</NO>
<PG>717-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nathan-2005" MODIFIED="2011-07-29 16:03:26 +1000" MODIFIED_BY="[Empty name]" NAME="Nathan 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-07-29 16:03:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nathan N, Borel T, Djibo A, Evans D, Djibo S, Corty JF et al</AU>
<TI>Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<NO>9482</NO>
<PG>308-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Odio-1986" MODIFIED="2011-07-29 16:04:34 +1000" MODIFIED_BY="[Empty name]" NAME="Odio 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-07-29 16:04:34 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Odio CM, Faingezicht I, Salas JL, Guevara J, Mohs E, McCracken GH Jr</AU>
<TI>Cefotaxime vs conventional therapy for the treatment of bacterial meningitis of infants and children</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>1986</YR>
<VL>5</VL>
<NO>4</NO>
<PG>402-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peltola-1989" MODIFIED="2011-07-29 16:04:59 +1000" MODIFIED_BY="[Empty name]" NAME="Peltola 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-07-29 16:04:59 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peltola H, Anttila M, Renkonen OV; Finnish Study Group</AU>
<TI>Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>8650</VL>
<NO>1</NO>
<PG>1281-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguz-1985" NAME="Rodriguz 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez WJ, Puig JR, Khan WN, Feris J, Gold BG, Sturla C</AU>
<TI>Ceftazidime vs. standard therapy for pediatric meningitis: therapeutic, pharmacologic and epidemiologic observations</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>1986</YR>
<VL>5</VL>
<NO>4</NO>
<PG>408-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-1996" NAME="Sharma 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma PR, Adhikarai RK, Joshi MP, Lal M, Chodon T, Pokhrel BM</AU>
<TI>Intravenous chloramphenicol plus penicillin versus intramuscular ceftriaxone for the treatment of pyogenic meningitis in Nepalese children (letter to the editor)</TI>
<SO>Tropical Doctor</SO>
<YR>1996</YR>
<VL>26</VL>
<NO>2</NO>
<PG>84-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steele-1983" MODIFIED="2011-07-29 16:07:00 +1000" MODIFIED_BY="[Empty name]" NAME="Steele 1983" YEAR="1983">
<REFERENCE MODIFIED="2011-07-29 16:07:00 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steele RW, Bradsher RW</AU>
<TI>Comparison of ceftriaxone with standard therapy for bacterial meningitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1983</YR>
<VL>103</VL>
<NO>1</NO>
<PG>138-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuncer-1988" MODIFIED="2011-07-29 16:07:47 +1000" MODIFIED_BY="[Empty name]" NAME="Tuncer 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-07-29 16:07:47 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuncer MA, Gur I, Ertem U, Ece A, Turkmen S, Deniz B et al</AU>
<TI>Once daily ceftriaxone for meningococcemia and meningococcal meningitis</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>10</NO>
<PG>711-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wells-1984" NAME="Wells 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wells TG, Trang JM, Brown AL, Marmer BC, Jacobs RF</AU>
<TI>Cefotaxime therapy of bacterial meningitis in children</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1984</YR>
<VL>14</VL>
<NO>Suppl B</NO>
<PG>81-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-05-29 04:44:28 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Chartrand-1984" NAME="Chartrand 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chartrand SA, Marks MI, Scribner RK, Johnston JT, Frederick DF</AU>
<TI>Moxalactam therapy of Haemophilus influenzae type b meningitis in children</TI>
<SO>Journal of Pediatrics</SO>
<YR>1984</YR>
<VL>104</VL>
<NO>3</NO>
<PG>454-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donma-1992" NAME="Donma 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Donma MM, Donma O</AU>
<TI>Cephalosporins in childhood bacterial meningitis</TI>
<SO>Journal of the Singapore Paediatric Society</SO>
<YR>1992</YR>
<VL>34</VL>
<NO>3-4</NO>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dutta-1979" NAME="Dutta 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dutta AK, Sehgal H, Khandpur SC</AU>
<TI>Evaluation of ampicillin in the treatment of acute bacterial meningitis in children</TI>
<SO>Indian Pediatrics</SO>
<YR>1979</YR>
<VL>16</VL>
<NO>3</NO>
<PG>239-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feldstein-1987" NAME="Feldstein 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Feldstein TJ, Uden DL, Larson TA</AU>
<TI>Cefotaxime for treatment of gram-negative bacterial meningitis in infants and children</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>5</NO>
<PG>471-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hohl-1990" NAME="Hohl 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hohl P, Martin E, Kayser FH</AU>
<TI>Short course single daily ceftriaxone monotherapy for acute bacterial meningitis in children: results of a Swiss multicenter study. Part II: Bacteriological results</TI>
<SO>Infection</SO>
<YR>1990</YR>
<VL>18</VL>
<NO>2</NO>
<PG>78-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaplan-1988a" NAME="Kaplan 1988a" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan SL, Mason SK, Mason EO Jr, Murphy M, Smith EO</AU>
<TI>Follow-up of prospective randomized trial of ampicillin or chloramphenicol versus moxalactam treatment of Haemophilus influenzae type b meningitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1988</YR>
<VL>112</VL>
<NO>5</NO>
<PG>795-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kavaliotis-1989" NAME="Kavaliotis 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kavaliotis J, Manios SG, Kansouzidou A, Danielidis V</AU>
<TI>Treatment of childhood bacterial meningitis with ceftriaxone once daily: open, prospective, randomized, comparative study of short-course versus standard-length therapy</TI>
<SO>Chemotherapy</SO>
<YR>1989</YR>
<VL>35</VL>
<NO>4</NO>
<PG>296-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kobayashi-1981" NAME="Kobayashi 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kobayashi Y, Morikawa Y, Haruta T, Fujii R, Meguro H, Hori M</AU>
<TI>Clinical evaluation of cefotaxime in the treatment of purulent meningitis in children</TI>
<SO>Japanese Journal of Antibiotics</SO>
<YR>1981</YR>
<VL>34</VL>
<NO>6</NO>
<PG>946-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumar-1993" NAME="Kumar 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar P, Verma IC</AU>
<TI>Antibiotic therapy for bacterial meningitis in children in developing countries</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1993</YR>
<VL>71</VL>
<NO>2</NO>
<PG>183-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapointe-1984" NAME="Lapointe 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lapointe JR, Beliveau C, Chicoine L, Joncas JH</AU>
<TI>A comparison of ampicillin-cefotaxime and ampicillin-chloramphenicol in childhood bacterial meningitis: an experience in 55 patients</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1984</YR>
<VL>14</VL>
<NO>B</NO>
<PG>167-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macfarlane-1979" NAME="Macfarlane 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macfarlane JT, Anjorin FI, Cleland PG, Hassan-King M, Tor-Agbidye S, Wali SS</AU>
<TI>Single injection treatment of meningococcal meningitis. 1. Long-acting penicillin</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1979</YR>
<VL>73</VL>
<NO>6</NO>
<PG>693-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marks-1986" NAME="Marks 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marks WA, Stutman HR, Marks MI, Abramson JS, Ayoub EM, Chartrand SA et al</AU>
<TI>Cefuroxime versus ampicillin plus chloramphenicol in childhood bacterial meningitis: a multicenter randomized controlled trial</TI>
<SO>Journal of Pediatrics</SO>
<YR>1986</YR>
<VL>109</VL>
<NO>1</NO>
<PG>123-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1990" NAME="Martin 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin E, Hohl P, Guggi T, Kayser FH, Fernex M</AU>
<TI>Short course single daily ceftriaxone monotherapy for acute bacterial meningitis in children: results of a Swiss multicenter study. Part I: Clinical results</TI>
<SO>Infection</SO>
<YR>1990</YR>
<VL>18</VL>
<NO>2</NO>
<PG>70-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ngu-1987" NAME="Ngu 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ngu J, Youmbissi T</AU>
<TI>A comparative study with ceftriaxone (Rocephin) versus ampicillin and chloramphenicol in children with bacterial meningitis</TI>
<SO>Chemioterapia</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>Suppl 2</NO>
<PG>417-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pecoul-1991" NAME="Pecoul 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pecoul B, Varaine F, Keita M, Soga G, Djibo A, Soula G et al</AU>
<TI>Long-acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<NO>8771</NO>
<PG>862-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfister-1989" NAME="Pfister 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pfister HW, Preac-Mursic V, Wilske B, Einhaupl KM</AU>
<TI>Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study</TI>
<SO>Archives of Neurology</SO>
<YR>1989</YR>
<VL>46</VL>
<NO>11</NO>
<PG>1190-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Powell-1990" NAME="Powell 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Powell KR, Sugarman LI, Eskenazi AE, Woodin KA, Kays MA, McCormick KL et al</AU>
<TI>Normalization of plasma arginine vasopressin concentrations when children with meningitis are given maintenance plus replacement fluid therapy</TI>
<SO>Journal of Pediatrics</SO>
<YR>1990</YR>
<VL>117</VL>
<NO>4</NO>
<PG>515-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reed-1983" NAME="Reed 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reed MD, Rekate HL, Aronoff SC, Myers CM, Blumer JL</AU>
<TI>Single-dose plasma and cerebrospinal fluid pharmacokinetics of ceftriaxone in infants and children</TI>
<SO>Clinical Pharmacology</SO>
<YR>1983</YR>
<VL>2</VL>
<NO>6</NO>
<PG>558-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez-1985" NAME="Rodriguez 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez WJ, Khan WN, Gold B, Feris J, Puig J, Sturla C</AU>
<TI>Ceftazidime in the treatment of meningitis in infants and children over one month of age</TI>
<SO>American Journal of Medicine</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>2A</NO>
<PG>52-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaad-1990" NAME="Schaad 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaad UB, Suter S, Gianella-Borradori A, Pfenninger J, Auckenthaler R, Bernath O et al</AU>
<TI>A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children</TI>
<SO>New England Journal of Medicine</SO>
<YR>1990</YR>
<VL>322</VL>
<NO>3</NO>
<PG>141-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steele-1984" NAME="Steele 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Steele RW</AU>
<TI>Ceftriaxone therapy of meningitis and serious infections</TI>
<SO>American Journal of Medicine</SO>
<YR>1984</YR>
<VL>77</VL>
<NO>4C</NO>
<PG>50-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tessin-1989" NAME="Tessin 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tessin I, Trollfors B, Thiringer K, Thorn Z, Larsson P</AU>
<TI>Concentrations of ceftazidime, tobramycin and ampicillin in the cerebrospinal fluid of newborn infants</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1989</YR>
<VL>148</VL>
<NO>7</NO>
<PG>679-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tetanye-E_x002c_-1990" NAME="Tetanye E, 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tetanye E, Yondo D, Bernard-Bonnin AC, Tchokoteu PF, Kago I, Ndayo M</AU>
<TI>Initial treatment of bacterial meningitis in Yaounde, Cameroon: theoretical benefits of the ampicillin-chloramphenicol combination versus chloramphenicol alone</TI>
<SO>Annals of Tropical Pediatrics</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>3</NO>
<PG>285-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vallejo-1991" NAME="Vallejo 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vallejo JG, Kaplan SL, Mason EO Jr</AU>
<TI>Treatment of meningitis and other infections due to ampicillin-resistant Haemophilus influenzae type b in children</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>2</NO>
<PG>197-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wazib-2008" MODIFIED="2011-05-29 04:44:28 +1000" MODIFIED_BY="[Empty name]" NAME="Wazib 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-05-29 04:44:28 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wazib A, Hossain MZ, Hanan R, Alam MB</AU>
<TI>A comparative study of benzylpenicillin versus ceftriaxone in the treatment of adult pyogenic meningitis</TI>
<SO>Journal of Dhaka Medical College</SO>
<YR>2008</YR>
<VL>17</VL>
<NO>2</NO>
<PG>59-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yogev-1986" NAME="Yogev 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yogev R, Shulman ST, Chadwick EG, Davis AT, Glogowski W</AU>
<TI>Once daily ceftriaxone for central nervous system infections and other serious pediatric infections</TI>
<SO>Pediatric Infectious Diseases</SO>
<YR>1986</YR>
<VL>5</VL>
<NO>3</NO>
<PG>298-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zavala-1988" NAME="Zavala 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zavala I, Barrera E, Nava A</AU>
<TI>Ceftriaxone in the treatment of bacterial meningitis in adults</TI>
<SO>Chemotherapy</SO>
<YR>1988</YR>
<VL>34</VL>
<NO>1</NO>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-08-09 13:49:12 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-08-09 13:49:12 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" NOTES="&lt;p&gt;DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986; 7(3):177- 88&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2011-07-29 17:03:21 +1000" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" NOTES="&lt;p&gt;Dickersin 1994. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994; 309:1286-91.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-07-29 17:03:21 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Enting-1996" MODIFIED="2011-07-29 17:07:00 +1000" MODIFIED_BY="[Empty name]" NAME="Enting 1996" TYPE="JOURNAL_ARTICLE">
<AU>Enting RH, Spanjaard L, Van de Beek D, Hensen EF, De Gans J, Dankert J</AU>
<TI>Antimicrobial susceptibility of Haemophilus influenzae, Neisseria meningitidis and Streptococcus pneumoniae isolates causing meningitis in The Netherlands, 1993-1994</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1996</YR>
<VL>38</VL>
<NO>5</NO>
<PG>777-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2011-08-03 15:09:19 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<IDENTIFIERS MODIFIED="2011-06-06 18:28:42 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2011-07-30 14:22:08 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnston-2007" MODIFIED="2011-08-09 13:49:01 +1000" MODIFIED_BY="[Empty name]" NAME="Johnston 2007" TYPE="COCHRANE_REVIEW">
<AU>Johnston BC, Supina AL, Ospina M, Vohra S</AU>
<TI>Probiotics for the prevention of pediatric antibiotic-associated diarrhea</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-08-09 13:49:01 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-08-09 13:49:01 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004827.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kaplan-1988b" MODIFIED="2011-07-29 17:09:05 +1000" MODIFIED_BY="[Empty name]" NAME="Kaplan 1988b" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan SL, Fishman MA</AU>
<TI>Update on bacterial meningitis</TI>
<SO>Journal of Child Neurology</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>2</NO>
<PG>82-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2011-08-03 15:09:49 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mwangi-2002" MODIFIED="2011-07-29 17:21:48 +1000" MODIFIED_BY="[Empty name]" NAME="Mwangi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Mwangi I, Berkley J, Lowe B, Peshu N, Marsh K, Newton CRJC</AU>
<TI>Acute bacterial meningitis in children admitted to a rural Kenyan Hospital: increasing antibiotic resistance and outcome</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1042-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pillai-2008" MODIFIED="2011-08-09 13:49:12 +1000" MODIFIED_BY="[Empty name]" NAME="Pillai 2008" TYPE="COCHRANE_REVIEW">
<AU>Pillai A, Nelson RL</AU>
<TI>Probiotics for treatment of Clostridium difficile associated colitis in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-08-09 13:49:12 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-08-09 13:49:12 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004611.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reis-2002" NAME="Reis 2002" TYPE="JOURNAL_ARTICLE">
<AU>Reis JN, Lima JB, Ribeiro GS, Corderio SM, Salgado K, Reis MG et al</AU>
<TI>Antimicrobial resistance in Haemophilus influenzae isolated during population-based surveillance for meningitis in Salvador, Brazil</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>11</NO>
<PG>3641-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-06-22 14:16:05 +1000" MODIFIED_BY="Liz Dooley" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<PB>The Nordic Cochrane Centre. The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sutcliffe1988" MODIFIED="2011-07-29 17:22:59 +1000" MODIFIED_BY="[Empty name]" NAME="Sutcliffe1988" TYPE="JOURNAL_ARTICLE">
<AU>Sutcliffe EM, Jones DM, El-Sheikh S, Percival A</AU>
<TI>Penicillin insensitive meningococci in the UK</TI>
<SO>Lancet</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>8586</NO>
<PG>82-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tristram-2007" NAME="Tristram 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tristram S, Jacobs MR, Appelbaum PC</AU>
<TI>Antimicrobial resistance in Haemophilus influenzae</TI>
<SO>Clinical Microbiology Reviews</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>2</NO>
<PG>368-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wasfy-2005" MODIFIED="2011-07-29 17:24:11 +1000" MODIFIED_BY="[Empty name]" NAME="Wasfy 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wasfy MO, Pimentel G, Abdel-Mansoud M, Russell KL, Barrozo CP, Klena JD et al</AU>
<TI>Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae causing meningitis in Egypt, 1998-2003</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2005</YR>
<VL>55</VL>
<NO>6</NO>
<PG>958-64</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-07-01 09:10:57 +1000" MODIFIED_BY="Liz Dooley">
<REFERENCE ID="REF-Prasad-2004" MODIFIED="2008-07-01 09:10:57 +1000" MODIFIED_BY="Liz Dooley" NAME="Prasad 2004" TYPE="COCHRANE_REVIEW">
<AU>Prasad K, Singhal T, Jain N, Gupta PK</AU>
<TI>Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-07-01 09:10:57 +1000" MODIFIED_BY="Liz Dooley">
<IDENTIFIER MODIFIED="2008-07-01 09:10:57 +1000" MODIFIED_BY="Liz Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD001832.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-08-01 10:59:41 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-08-01 10:59:41 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-07-29 14:45:42 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aronoff-1984">
<CHAR_METHODS MODIFIED="2011-07-29 14:44:46 +1000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation unclear; unclear blinding status; ITT unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age 0.17 to 8.75 years (mean 2.46 years); both sexes; duration of illness before onset of therapy not clear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-29 14:45:26 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: ceftriaxone; control arm: ampicillin-chloramphenicol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-29 14:45:42 +1000" MODIFIED_BY="[Empty name]">
<P>Death; sensorineural deafness; hydrocephalus and blindness</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 15:50:44 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barson-1985">
<CHAR_METHODS MODIFIED="2011-06-22 14:26:56 +1000" MODIFIED_BY="Liz Dooley">
<P>Computer-generated random numbers used for randomisation, but concealment unclear; blinding status unclear; 4 patients excluded from analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 15:49:58 +1000" MODIFIED_BY="[Empty name]">
<P>Age 0.2 to 5 years; both sexes; duration of illness before therapy 2.4 days; number comatosed not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 15:50:15 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: ceftriaxone; control arm: ampicillin-chloramphenicol for 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 15:50:44 +1000" MODIFIED_BY="[Empty name]">
<P>Death; sensorineural deafness; seizures and cranial nerve palsies</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:03:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bryan-1985">
<CHAR_METHODS MODIFIED="2011-07-30 16:03:34 +1000" MODIFIED_BY="[Empty name]">
<P>Allocation using random number allocation table<BR/>Unclear concealment<BR/>No blinding<BR/>No ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:01:13 +1000" MODIFIED_BY="[Empty name]">
<P>Age &gt; 2 months (94% 2 months to 17 years)<BR/>Both sexes<BR/>Clinically diagnosed ABM (pts evaluated if:<BR/>(a) survived &#8805; 6 hrs<BR/>(b) had CSF culture or gram stain proof of bacterial meningitis, or<BR/>(c) &gt; 10,000 leukocytes/mm<SUP>3</SUP> of CSF (predominantly polymorphonuclear leukocytes), protein concentration of &gt; 250 mg/dl and glucose concentration of = 20 mg/dl)<BR/>Patients with prior antibiotic usage were excluded from evaluation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:01:45 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: ceftriaxone (100 mg/kg i.v. loading dose followed by 80 mg/kg every 24 hrs)<BR/>Control arm: ampicillin (75 mg/kg i.v. loading dose followed by 50 mg/kg every 4 hours) and<BR/>chloramphenicol (50 mg/kg i.v. loading dose followed by 25 mg/kg every 6 hrs)<BR/>Duration of treatment: at least 10 days except in meningococcal group who were treated for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:02:43 +1000" MODIFIED_BY="[Empty name]">
<P>Death<BR/>Neurological sequelae during treatment and at the end of a variable follow-up period of a max of 1 month<BR/>Time for CSF sterility<BR/>Duration of fever<BR/>Adverse effects to ceftriaxone recorded were anaemia, transient mild neutropenia, diarrhoea and rash<BR/>Adverse effects in the control arm recorded were anaemia, transient moderate neutropenia and diarrhoea</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study done in Brazil. 10/36 evaluated were culture negative</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:10:57 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Congeni-1984">
<CHAR_METHODS MODIFIED="2011-07-30 16:03:24 +1000" MODIFIED_BY="[Empty name]">
<P>Allocation using computer-generated randomisation tables. <BR/>Unclear concealment<BR/>No blinding<BR/>No ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:03:43 +1000" MODIFIED_BY="[Empty name]">
<P>Age range: 1 day to 15 years<BR/>Both sexes<BR/>Criteria for diagnosis not mentioned</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:10:22 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: ceftriaxone (50 mg/kg i.v. every 12 hrs)<BR/>Control arm: ampicillin (200 to 400 mg/kg day i.v. in 4 divided doses) and chloramphenicol (75 mg/kg/day i.v. 6 hrly). Neonates were given gentamycin 2.5 mg/kg i.v. 8 hrly<BR/>1 patient in conventional therapy group received nafcillin as the agent <I>Staphylococcus epidermidis</I> (<I>S. epidermidis)</I> was not susceptible to ampicillin or chloramphenicol<BR/>Duration of treatment not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:10:57 +1000" MODIFIED_BY="[Empty name]">
<P>Death<BR/>Complications and sequelae during the period of treatment<BR/>Time for CSF sterility<BR/>Duration of fever<BR/>Potential adverse effects in ceftriaxone group recorded were transient eosinophilia, transient neutropenia, anaemia and mild diarrhoea<BR/>Adverse effect recorded in conventional therapy group was mild diarrhoea</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-22 14:30:51 +1000" MODIFIED_BY="Liz Dooley">
<P>Study done in the USA<BR/>Culture negative were excluded from the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:12:17 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Del-Rio-1983">
<CHAR_METHODS MODIFIED="2011-07-30 16:11:21 +1000" MODIFIED_BY="[Empty name]">
<P>Random allocation, but method of randomisation and concealment not mentioned<BR/>Unclear blinding status</P>
<P>No ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients above 6 weeks of age (66/78 &lt; 2 years). Patients with suspected or definite meningitis enrolled. Those with positive cultures and/or characteristic CSF findings were subsequently analysed. (Criteria for CSF findings not mentioned)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:11:49 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: ceftriaxone (75 mg/kg i.v. loading dose followed by 50 mg/kg/dose i.v. 12 hrly)<BR/>Control arm: ampicillin (200 mg/kg/day i.v. 6 hrly) and chloramphenicol (100 mg/kg/day i.v. 6 hrly)<BR/>Duration of therapy: 7 days in both groups for meningococcal meningitis and 10 days for others</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:12:17 +1000" MODIFIED_BY="[Empty name]">
<P>Death<BR/>Sensorineural deafness (defined as &gt; 30 dB hearing loss)<BR/>Other disabilities<BR/>Duration of fever<BR/>Duration of follow-up: 1 to 5 months<BR/>Adverse effects noted in ceftriaxone group were diarrhoea, arthritis, phlebitis, raised SGOT and drug fever<BR/>Adverse effects noted in conventional therapy group were diarrhoea, arthritis and drug fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-22 14:31:30 +1000" MODIFIED_BY="Liz Dooley">
<P>Study done in the USA<BR/>72/92 enrolled were culture positive</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:13:34 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Filali-1993">
<CHAR_METHODS MODIFIED="2011-07-30 16:12:46 +1000" MODIFIED_BY="[Empty name]">
<P>Random allocation, but method of randomisation and concealment not mentioned<BR/>Unclear blinding status<BR/>ITT analysis (?)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:12:53 +1000" MODIFIED_BY="[Empty name]">
<P>Age more than 16 yrs (mean age 28.9 years)<BR/>Both sexes (more males in control group than in experimental group)<BR/>Diagnosis of meningococcal meningitis based on a positive CSF culture or detection of meningococcal polysaccharide antigen in CSF. Also, if a patient presented with the characteristic clinical findings of meningitis and purulent CSF during an epidemic, a diagnosis of meningococcal meningitis was accepted</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:13:17 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: ceftriaxone (2 g i.v. daily for 2 days)<BR/>Control arm: penicillin G (300,000 IU/kg/day 4 hrly for 6 days)<BR/>1/16 patients randomised to ceftriaxone group had to be given ceftriaxone for 7 days due to severity of disease<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:13:34 +1000" MODIFIED_BY="[Empty name]">
<P>Death<BR/>Neurological sequelae<BR/>Duration of coma<BR/>Duration of fever</P>
<P>Duration of follow-up: 2 months after discharge<BR/>No adverse effects noted in either group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study conducted in Morocco</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:14:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Girgis-1987">
<CHAR_METHODS MODIFIED="2011-07-30 16:13:56 +1000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation not described; unclear blinding status; only 30 out of 50 enrolled were analysed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:14:12 +1000" MODIFIED_BY="[Empty name]">
<P>Age 16 to 30 years; both sexes; duration of illness before therapy less than 4 days; nearly two-third comatosed in each group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:14:32 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: ceftriaxone (100 mg/kg/24 hrs i.m. to children i.v. to adults)<BR/>Control arm: ampicillin (160 mg/kg/day 6 hrly and chloramphenicol (100 mg/kg/day 6 hrly<BR/>Duration of therapy according to response</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death; duration of fever</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study conducted in Egypt</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:15:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Girgis-1988">
<CHAR_METHODS MODIFIED="2011-07-30 16:15:10 +1000" MODIFIED_BY="[Empty name]">
<P>Random allocation but method of randomisation and concealment not mentioned<BR/>Unclear blinding status<BR/>ITT analysis (?)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:15:17 +1000" MODIFIED_BY="[Empty name]">
<P>Age range: 5 months to 28 years<BR/>Both sexes; patients with signs and symptoms of meningitis randomised. Patients from whom organisms were isolated in CSF were included in final analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:15:29 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: ceftriaxone (100 mg/kg/24 hrs i.m. to children i.v. to adults)<BR/>Control arm: ampicillin (160 mg/kg/day 6 hrly i.m. to children i.v. to adults) and chloramphenicol (100 mg/kg/day 6 hrly i.m. to children i.v. to adults)<BR/>Duration of therapy not specified</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:15:58 +1000" MODIFIED_BY="[Empty name]">
<P>Death<BR/>Days to become fully alert<BR/>Duration of fever<BR/>Duration of follow-up not mentioned<BR/>Adverse effects recorded were mild diarrhoea and cramps, nausea in either group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study conducted in Egypt<BR/>Only those included in analysis from whom organisms were isolated from CSF</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:17:41 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haffejee-1988">
<CHAR_METHODS MODIFIED="2011-07-30 16:16:34 +1000" MODIFIED_BY="[Empty name]">
<P>Random allocation but method of randomisation and concealment not mentioned<BR/>Single blinding mentioned but method of blinding not clear<BR/>No ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:16:38 +1000" MODIFIED_BY="[Empty name]">
<P>Age range: 1 month to 9 years<BR/>Both sexes<BR/>Diagnosed bacterial meningitis on the basis of Gram stain of CSF and/or CSF culture<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:16:54 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: cefotaxime (100 to 200 mg/kg/d i.v. for initial 3 to 5 days followed by i.m. for the rest of the duration in 2 or 3 divided doses)<BR/>Control arm: penicillin G (0.5 - 1 million I.U. 6 hourly i.v. for initial 3 to 5 days followed by i.m. for the rest of the duration) and chloramphenicol (80 to 100 mg/kg/day orally in 3 to 4 divided doses)<BR/>Sulphadiazine (100 mg/kg/day orally) was also given to 8/15 analysed in the control arm</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:17:27 +1000" MODIFIED_BY="[Empty name]">
<P>Death<BR/>Sensorineural deafness<BR/>Other disabilities<BR/>Duration of fever<BR/>Mean duration of follow-up: 27.1 months<BR/>Adverse effects noted in cefotaxime group were diarrhoea, neutropenia, anaemia and thrombocytosis<BR/>Adverse effects noted in conventional therapy group were all the above plus thrombocytopaenia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-07-30 16:17:41 +1000" MODIFIED_BY="[Empty name]">
<P>Study conducted in South Africa<BR/>Sulfadiazine used in first 18 months of 52 month-long trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:19:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jacobs-1985">
<CHAR_METHODS MODIFIED="2011-07-30 16:18:00 +1000" MODIFIED_BY="[Empty name]">
<P>Random allocation, but method and concealment unclear<BR/>Unclear blinding status<BR/>No ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:18:03 +1000" MODIFIED_BY="[Empty name]">
<P>Age range: 1 week to 16 years<BR/>Both sexes<BR/>Criteria for diagnosis not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:18:26 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: cefotaxime (50 mg/kg/dose i.v. 6 hrly)<BR/>Control arm: ampicillin (50 to 100 mg/kg/dose i.v. 6 hrly) plus chloramphenicol or gentamicin<BR/>Chloramphenicol was given 25 mg/kg/dose i.v. 6 hrly<BR/>Gentamycin for neonates was given in a dose of 2.5 mg/kg/dose 8 to 12 hrly<BR/>Mean duration of cefotaxime therapy: 11.1 days<BR/>Mean duration of conventional therapy: 11.9 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:19:13 +1000" MODIFIED_BY="[Empty name]">
<P>Death<BR/>Sensorineural deafness<BR/>other sequelae<BR/>Duration of fever<BR/>Minimum duration of follow-up: 3 months<BR/>Adverse effects in cefotaxime group: diarrhoea<BR/>Adverse effects in conventional therapy group: acute tubular necrosis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-22 14:34:45 +1000" MODIFIED_BY="Liz Dooley">
<P>Study conducted in the USA<BR/>Culture negative patients were excluded from evaluation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:20:11 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Narciso-1983">
<CHAR_METHODS MODIFIED="2011-07-30 16:19:37 +1000" MODIFIED_BY="[Empty name]">
<P>Random allocation, but method and concealment unclear<BR/>Unclear blinding status<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:19:41 +1000" MODIFIED_BY="[Empty name]">
<P>Age: mean age 46 years (all adults)<BR/>Sex distribution not clear<BR/>Criteria for diagnosis not specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:20:02 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: ceftriaxone (80 to 100 mg/kg/day i.v. 12 hrly)<BR/>Control arm: ampicillin (110 mg/kg/day i.v. 8 hrly)<BR/>Dosages were halved in both groups when meningeal symptoms disappeared<BR/>Duration of treatment: treatment continued until cells in CSF became normal</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:20:11 +1000" MODIFIED_BY="[Empty name]">
<P>Death<BR/>Duration of coma<BR/>Duration of fever<BR/>Duration of follow-up: until discharge</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study done in Italy<BR/>7/10 were culture positive</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:21:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nathan-2005">
<CHAR_METHODS MODIFIED="2011-06-22 14:35:32 +1000" MODIFIED_BY="Liz Dooley">
<P>Allocation using computer-generated list and sealed envelopes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:21:05 +1000" MODIFIED_BY="[Empty name]">
<P>Age: median age 7 years (all patients &gt; 2 months)<BR/>Both sexes<BR/>Patients who had suspected meningitis on the basis of fever in last 24 hrs/ sudden onset of fever along with at least one of the following: neck stiffness, impaired consciousness, or petechial rash (&gt; 1 yr); or bulging fontanel, axial hypotonia, upwardly gazing or petechial rash (&lt; 1 year)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:21:48 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm : ceftriaxone (100 mg/kg/day i.m. up to a maximum dose of 4 g; 2nd dose of 75 mg/kg at 24 to 48 hrs. In case of clinical failure. Control arm: oily suspension of chloramphenicol (100 mg/kg/day i.m. up to a max. dose of 3 g; 2nd dose of 100 mg/kg in case of clinical failure at 24 to 48 hrs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-22 14:52:36 +1000" MODIFIED_BY="Liz Dooley">
<P>Death<BR/>Overall treatment failure (death or clinical failure at 72 h defined as state of consciousness remaining severely altered, no improvement in the state of consciousness since 0 hrs, repeated or persistent convulsions, worsened neurological symptoms since 0 hrs, axillary temperature &gt; 38.5C)<BR/>Neurological sequelae at 72 h</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-22 14:36:27 +1000" MODIFIED_BY="Liz Dooley">
<P>Study done in eastern Niger for 1 month during a meningitis epidemic</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:23:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Odio-1986">
<CHAR_METHODS MODIFIED="2011-07-30 16:22:29 +1000" MODIFIED_BY="[Empty name]">
<P>Patients were assigned treatment from a list of randomised therapy assignments<BR/>Concealment unclear<BR/>Unclear blinding status<BR/>No ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:22:34 +1000" MODIFIED_BY="[Empty name]">
<P>Age range: 2 months to 10.5 years<BR/>Both sexes<BR/>Pts who had suspected bacterial meningitis on the basis of identification of microbes on gram stained smear of CSF or proved bacterial meningitis were eligible for the study<BR/>However, patients with culture proved bacterial meningitis were enrolled and evaluated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:22:53 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: cefotaxime (50 mg/kg/dose i.v. 6 hrly for at least 10 days (mean duration 12.7 days)<BR/>Control arm: ampicillin (50 mg/kg/dose i.v. 6 hrly for first 5 days) and chloramphenicol (25 mg/kg/dose i.v. 6 hrly for 5 days followed by oral administration for at least 10 days). Mean duration of therapy in control group was 11.7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:23:33 +1000" MODIFIED_BY="[Empty name]">
<P>Death<BR/>Sensory sequelae including visual auditory and co-ordination problems<BR/>Inability to perform ADL<BR/>Developmental abnormalities<BR/>Duration of fever<BR/>Other sequelae<BR/>Duration of follow-up: at least 4 months<BR/>Adverse effects noted in the experimental group were diarrhoea, thrombocytosis, neutropaenia, skin rash, prolonged fever, elevated ALT, elevated blood urea nitrogen and hyperkalaemia<BR/>Adverse effects noted in conventional therapy group were diarrhoea, neutropenia, prolonged fever and elevated ALT<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study conducted in Costa Rica<BR/>16/42 in experimental arm and 18/43 in conventional therapy group had already received previous antibiotics<BR/>Neonates were initially included in the study but later excluded from analysis<BR/>Pts were evaluated for sequelae at the time of discharge and at the end of 4 months or longer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 17:42:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peltola-1989">
<CHAR_METHODS MODIFIED="2011-07-30 16:24:19 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised into 4 treatment groups using a list<BR/>Concealment<BR/>Blinding unclear<BR/>No ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 17:42:39 +1000" MODIFIED_BY="[Empty name]">
<P>Age range: 3 months to 15 years<BR/>Both sexes<BR/>Patients diagnosed having ABM if CSF culture was positive or for culture negative cases, presence of signs and symptoms, total leucocyte count &gt; 100 /microlitre and 1 or more of the following: a positive blood culture; bacteria in CSF by gram stain; or positive serology<BR/>Also, if the patient presented with a characteristic clinical picture and showed high CSF leucocyte count, serum C-reactive protein of 20 mg/L or above, or CSF lactate &#8805; 3 mg/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:25:38 +1000" MODIFIED_BY="[Empty name]">
<P>4 treatment groups as under:<BR/>1) chloramphenicol (100 mg/kg/day i.v. in 4 divided doses)<BR/>2) ampicillin (250 mg/kg/day i.v. in 4 divided doses<BR/>3) cefotaxime (150 mg/kg/day in 4 divided doses<BR/>4) ceftriaxone (100 mg/kg/day i.v. once daily)<BR/>The first dose of all drugs was increased by 50%<BR/>All drugs were given for 7 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:26:06 +1000" MODIFIED_BY="[Empty name]">
<P>Death<BR/>Sensorineural deafness<BR/>Recurrence of bacterial meningitis<BR/>Duration of consciousness impairment<BR/>Duration of fever<BR/>Duration of follow-up: 12 months after discharge<BR/>Adverse effects noted in the ceftriaxone group were diarrhoea, gall bladder precipitate<BR/>Diarrhoea was also noted in the other groups<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-06 16:28:45 +1000" MODIFIED_BY="[Empty name]">
<P>Study conducted in Finland<BR/>183/191 culture positive initially</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 17:44:33 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rodriguz-1985">
<CHAR_METHODS MODIFIED="2011-07-30 16:26:30 +1000" MODIFIED_BY="[Empty name]">
<P>Random allocation but method and concealment unclear<BR/>Unclear blinding status<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 17:44:33 +1000" MODIFIED_BY="[Empty name]">
<P>Children over 1 month of age (84% &#8804; 3 yrs)<BR/>Both sexes<BR/>Criteria for diagnosis of ABM not mentioned<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:26:44 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental group: ceftazidime (150 mg/kg/day i.v. in three doses for mean duration of 10.2 days)<BR/>Control group: ampicillin (400 mg/kg/d i.v. 6 hrly) and chloramphenicol (75-100 mg/kg/d ay 6 hrly for a mean duration of 9.5 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:27:10 +1000" MODIFIED_BY="[Empty name]">
<P>Death<BR/>Other sequelae (hearing loss not assessed)<BR/>Duration of fever<BR/>Days until asymptomatic<BR/>Duration of follow-up not mentioned<BR/>Adverse effects recorded in ceftazidime group were diarrhoea, drug fever and leukopenia/anaemia requiring blood transfusion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study done in Dominican Republic</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:28:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharma-1996">
<CHAR_METHODS MODIFIED="2011-07-30 16:27:38 +1000" MODIFIED_BY="[Empty name]">
<P>Random allocation mentioned, but method and concealment not clear<BR/>Unclear blinding status<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:28:14 +1000" MODIFIED_BY="[Empty name]">
<P>Age range 5 months to 5 years<BR/>Both sexes<BR/>Diagnosed ABM on clinical and CSF grounds<BR/>(Clinical features: fever of acute onset, vomiting, convulsion, bulging fontanel in infants<BR/>CSF features: cell count &gt; 100 with &gt; 60% polymorphs<BR/>Latex agglutination test was also done</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:28:27 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: ceftriaxone (50 mg/kg/day i.m. in a single dose for 7 days)<BR/>Control arm: chloramphenicol (100 mg/kg/day i.v. 6 hrly for 14 days) and benzylpenicillin (200,000 IU/kg/day 6 hourly for 14 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Deaths<BR/>Duration of fever<BR/>Adverse outcome events not mentioned<BR/>No data on sequelae<BR/>Followed till discharge<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study done in Nepal<BR/>No culture data provided<BR/>Organisms identified by CSF agglutination test</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:30:24 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steele-1983">
<CHAR_METHODS MODIFIED="2011-07-30 16:29:08 +1000" MODIFIED_BY="[Empty name]">
<P>Random allocation mentioned, but method and concealment not clear<BR/>Unclear blinding status<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:29:10 +1000" MODIFIED_BY="[Empty name]">
<P>Age range: 14 days to 14 years<BR/>Both sexes<BR/>Patients with culture positive bacterial meningitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:29:58 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: ceftriaxone (100 mg/kg/day i.v. 12 hrly; i.m. route was used in some in last days of treatment)<BR/>Control arm: ampicillin (200 to 400 mg/kg/day i.v. 6 hrly) and chloramphenicol (100 mg/kg/day i.v. 6 hrly; orally in some in last days of treatment)<BR/>Duration of treatment in both the groups was 7 days for <I>N. meningitidis</I>; 10 days for <I>H. influenzae</I>; 14 days for <I>S. pneumoniae</I>; 21 days for other organisms</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:30:24 +1000" MODIFIED_BY="[Empty name]">
<P>Death<BR/>Sensorineural deafness<BR/>Other disabilities<BR/>Duration of fever<BR/>Duration of follow-up: 3 months after treatment<BR/>Adverse effects noted in the ceftriaxone group were diarrhoea (defined as &gt; 20 mg/kg/day stool) and anaemia<BR/>Adverse effects noted in the control group were the same<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-22 14:39:54 +1000" MODIFIED_BY="Liz Dooley">
<P>Study done in the USA<BR/>Also gives data on ceftriaxone pharmacokinetics as well as susceptibility</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:32:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tuncer-1988">
<CHAR_METHODS MODIFIED="2011-07-30 16:30:46 +1000" MODIFIED_BY="[Empty name]">
<P>Random allocation mentioned but method and concealment not clear<BR/>Unclear blinding status<BR/>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:31:34 +1000" MODIFIED_BY="[Empty name]">
<P>Age range: 1 month to 12 years<BR/>Both sexes<BR/>Patients having meningococcal meningitis diagnosed on clinical and CSF grounds<BR/>Criteria for diagnosis:<BR/>1) meningitis with or without purpura;<BR/>2) isolation of <I>N. meningitidis</I> from blood or CSF culture; or<BR/>3) positively stained smear of CSF for gram negative diplococci</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:31:51 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: ceftriaxone (80 to 100 mg/kg/day i.v. in a single dose for 4 days)<BR/>Control arm: penicillin G (500,000 IU/kg/day i.v. 4 hourly for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:32:27 +1000" MODIFIED_BY="[Empty name]">
<P>Deaths<BR/>Duration of fever<BR/>Reccurrence of disease within 6 months<BR/>Duration of follow-up: max. of 6 months<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-07-30 16:32:35 +1000" MODIFIED_BY="[Empty name]">
<P>Study done in Turkey<BR/>33% of patients had meningococcaemia without meningitis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-07-30 16:36:20 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wells-1984">
<CHAR_METHODS MODIFIED="2011-07-30 16:32:54 +1000" MODIFIED_BY="[Empty name]">
<P>Random allocation mentioned, but method and concealment not clear<BR/>Unclear blinding status<BR/>No ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-07-30 16:32:57 +1000" MODIFIED_BY="[Empty name]">
<P>Age range: 0.25 to 200 months<BR/>Both sexes<BR/>Pts. with clinically suspected meningitis and purulent CSF initially randomised<BR/>Those who were later shown to be culture proven viral meningitis or having sterile CSF were excluded from the analysis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-30 16:33:24 +1000" MODIFIED_BY="[Empty name]">
<P>Experimental arm: cefotaxime (50 mg/kg/dose i.v. 6 hrly for 10 to 14 days)<BR/>Control arm: ampicillin (50 to 100 mg/kg/dose i.v. 6 hrly for 10 to 14 days) plus chloramphenicol (25 mg/kg/dose 6 hrly i.v. for 10 to 14 days) or gentamycin (2.5 mg/kg/dose 8 to 12 hrly for 10 to 14 days for children &lt; 1 month of age)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-07-30 16:36:20 +1000" MODIFIED_BY="[Empty name]">
<P>Death<BR/>Sensorineural deafness<BR/>Other disabilities<BR/>Patients followed up until discharge<BR/>No adverse effects noted in the cefotaxime group. In the conventional therapy group ATN was recorded as a potential adverse effect</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-07-30 16:35:46 +1000" MODIFIED_BY="[Empty name]">
<P>Study done in USA; 30/37 randomised had culture positive for bacteria<BR/>No mention about sensorineural deafness in the result section, but in the methodology section they say they have evaluated hearing at discharge</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ABM: acute bacterial meningitis<BR/>ADL: activity of daily living<BR/>ALT: alanine transaminase<BR/>ATN: acute tubular necrosis<BR/>CSF: cerebrospinal fluid<BR/>dB: decibel<BR/>hrs: hours<BR/>i.v.: intravenous<BR/>i.m.: intramuscular<BR/>Pts: patients<BR/>SGOT: serum glutamic oxaloacetic transaminase<BR/>yrs: years<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-07-30 17:25:08 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Chartrand-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>In some patients ampicillin and moxalactam were combined</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Donma-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dutta-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no group with third generation cephalosporin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Feldstein-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hohl-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a pharmacokinetic study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kaplan-1988a">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kavaliotis-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no conventional therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kobayashi-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>A non-comparative study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kumar-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no third generation cephalosporin arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lapointe-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Macfarlane-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no third generation cephalosporin arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marks-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no third generation cephalosporin arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martin-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no conventional antibiotic arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ngu-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pecoul-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no third generation cephalosporin arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pfister-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients had neuroborreliosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-30 16:39:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Powell-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-30 16:39:19 +1000" MODIFIED_BY="[Empty name]">
<P>This is not a study comparing antibiotics; a study of fluid intake</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reed-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>A pharmacokinetic study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rodriguez-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study contains the same data as published later by Rodriguez in 1986, which is included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schaad-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>A study comparing ceftriaxone and cefuroxime, not conventional antibiotics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Steele-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>No data presented</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tessin-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ampicillin was added to ceftazidime arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tetanye-E_x002c_-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no third generation cephalosporin arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vallejo-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>A retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-12 14:33:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wazib-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-12 14:33:36 +1000" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yogev-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>A non-comparative study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-07-30 17:25:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zavala-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-07-30 17:25:08 +1000" MODIFIED_BY="[Empty name]">
<P>The meningitis was not community-acquired</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-08-01 10:59:41 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-07-30 16:27:22 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 18:22:20 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aronoff-1984">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-28 00:02:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barson-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-28 23:26:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bryan-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-28 00:03:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Congeni-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 18:19:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Rio-1983">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:31:59 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Filali-1993">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:32:49 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Girgis-1987">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:33:12 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Girgis-1988">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:34:02 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Haffejee-1988">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:34:48 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Jacobs-1985">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:35:25 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Narciso-1983">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-28 00:08:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nathan-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 18:24:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Odio-1986">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-28 00:09:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peltola-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-30 16:27:22 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguz-1985">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:39:02 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-1996">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:39:58 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Steele-1983">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:41:01 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-1988">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:42:10 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1984">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-06-22 14:39:05 +1000" MODIFIED_BY="Liz Dooley" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:26:34 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Aronoff-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:27:18 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Barson-1985">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:30:05 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Bryan-1985">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:30:56 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Congeni-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:31:35 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Del-Rio-1983">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:32:02 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Filali-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:32:51 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Girgis-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:33:14 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Girgis-1988">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:34:05 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Haffejee-1988">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:34:52 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Jacobs-1985">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:35:27 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Narciso-1983">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 16:59:29 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nathan-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:37:13 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Odio-1986">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:38:02 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Peltola-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 17:08:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguz-1985">
<DESCRIPTION>
<P>Not reported </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-22 14:39:05 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 17:10:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steele-1983">
<DESCRIPTION>
<P>Not reported </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 17:11:52 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-1988">
<DESCRIPTION>
<P>Not reported </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 17:12:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-07-30 16:35:59 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-22 14:26:37 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Aronoff-1984">
<DESCRIPTION>
<P>The study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-22 14:27:38 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Barson-1985">
<DESCRIPTION>
<P>The study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-18 22:54:47 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bryan-1985">
<DESCRIPTION>
<P>No blinded outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-05-28 00:03:17 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Congeni-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-22 14:31:37 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Del-Rio-1983">
<DESCRIPTION>
<P>Study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-22 14:32:06 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Filali-1993">
<DESCRIPTION>
<P>The study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-22 14:32:53 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Girgis-1987">
<DESCRIPTION>
<P>The study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-18 22:53:38 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Girgis-1988">
<DESCRIPTION>
<P>The study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-05-28 00:06:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haffejee-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-22 14:34:53 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Jacobs-1985">
<DESCRIPTION>
<P>Study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-18 22:57:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Narciso-1983">
<DESCRIPTION>
<P>Study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-07-30 16:22:17 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nathan-2005">
<DESCRIPTION>
<P>Study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-18 22:49:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Odio-1986">
<DESCRIPTION>
<P>The study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-18 22:57:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peltola-1989">
<DESCRIPTION>
<P>Study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-07-30 16:27:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguz-1985">
<DESCRIPTION>
<P>Study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-22 14:39:07 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-1996">
<DESCRIPTION>
<P>Study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-18 22:58:22 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steele-1983">
<DESCRIPTION>
<P>Study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-22 14:41:03 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-1988">
<DESCRIPTION>
<P>Study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-07-30 16:35:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1984">
<DESCRIPTION>
<P>Study did not address this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-08-01 10:56:00 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-20 22:21:13 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aronoff-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-28 00:02:18 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barson-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-21 21:21:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bryan-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-20 22:30:31 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Congeni-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-18 22:47:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Rio-1983">
<DESCRIPTION>
<P>insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-22 14:32:05 +1000" MODIFIED_BY="Liz Dooley" RESULT="NO" STUDY_ID="STD-Filali-1993">
<DESCRIPTION>
<P>No adverse effects noted in either group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-07-30 16:14:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Girgis-1987">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-21 21:18:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Girgis-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-20 22:38:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haffejee-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-08-01 10:53:45 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jacobs-1985">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-18 16:57:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Narciso-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-28 00:08:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nathan-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-20 22:46:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Odio-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-18 17:06:35 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peltola-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-18 17:08:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodriguz-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-07-30 16:28:53 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sharma-1996">
<DESCRIPTION>
<P>Adverse outcome events not mentioned; no data on sequelae</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-18 17:11:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steele-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-18 17:12:08 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tuncer-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-08-01 10:56:00 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1984">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-08-01 10:55:37 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-20 22:21:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aronoff-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 15:21:45 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barson-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 15:38:28 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bryan-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-21 21:21:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Congeni-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-20 22:32:00 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Del-Rio-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 16:40:43 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Filali-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-30 16:14:53 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Girgis-1987">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-21 21:18:43 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Girgis-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-20 22:39:06 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haffejee-1988">
<DESCRIPTION>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 16:56:14 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:54:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Narciso-1983">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-20 22:44:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nathan-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-20 22:46:20 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Odio-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 17:06:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peltola-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-18 17:08:44 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rodriguz-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:55:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-1996">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-20 22:50:25 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steele-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:55:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-1988">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-20 22:54:58 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wells-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-08-01 10:59:41 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-30 15:48:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aronoff-1984">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-30 15:51:31 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barson-1985">
<DESCRIPTION>
<P>2 patients developed absolute granulocytopenia while receiving chloramphenicol and switched to ampicillin group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:51:11 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bryan-1985">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:51:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Congeni-1984">
<DESCRIPTION>
<P>Insufficient Information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:52:35 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Del-Rio-1983">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:52:48 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Filali-1993">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-30 16:14:58 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Girgis-1987">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:53:09 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Girgis-1988">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:53:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haffejee-1988">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:53:52 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jacobs-1985">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:54:14 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Narciso-1983">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-28 00:08:19 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nathan-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:49:19 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Odio-1986">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:49:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peltola-1989">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:54:47 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguz-1985">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:55:00 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-1996">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:55:22 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steele-1983">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:55:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tuncer-1988">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 10:59:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1984">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-05-28 16:17:08 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-05-28 16:17:33 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-08-09 13:46:26 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-08-09 13:45:09 +1000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2011-05-30 08:58:47 +1000" MODIFIED_BY="[Empty name]">Third generation cephalosporins versus conventional therapy for acute bacterial meningitis</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>Third generation cephalosporins versus conventional therapy for acute bacterial meningitis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients treated for acute bacterial meningitis<BR/>
<B>Settings: </B>acute bacterial meningitis<BR/>
<B>Intervention:</B> third generation cephalosporins versus conventional therapy<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Third generation cephalosporins versus conventional therapy</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Death</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1496<BR/>(19)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>67 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>65 per 1000</B>
<BR/>(37 to 87)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>47 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>46 per 1000</B>
<BR/>(26 to 61)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Deafness</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>501<BR/>(10)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>118 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>83 per 1000</B>
<BR/>(28 to 127)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>72 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
<BR/>(17 to 78)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Culture positivity 10 to 48 hours start of treatment</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>442<BR/>(12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>117 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>58 per 1000</B>
<BR/>(7 to 117)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>25 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>12 per 1000</B>
<BR/>(1 to 25)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Diarrhoea</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>750<BR/>(12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>125 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>202 per 1000</B>
<BR/>(155 to 255)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>77 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>125 per 1000</B>
<BR/>(95 to 157)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Neutropenia</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>472<BR/>(10)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>54 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>29 per 1000</B>
<BR/>(-16 to 74)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>13 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>7 per 1000</B>
<BR/>(-4 to 18)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Skin rash</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>533<BR/>(8)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>16 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 1000</B>
<BR/>(-24 to 26)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Treatment failure (either death or deafness)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1496<BR/>(19)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>87 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>79 per 1000</B>
<BR/>(47 to 107)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>67 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>61 per 1000</B>
<BR/>(36 to 82)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2011-08-09 13:45:23 +1000" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2011-05-30 08:59:18 +1000" MODIFIED_BY="[Empty name]">Cephalosporins versus conventional therapy for H. influenzae meningitis</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TD COLSPAN="7">
<P>
<B>Cephalosporins versus conventional therapy for <I>H. influenzae</I> meningitis </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients treated for <I>H. influenzae</I> meningitis<BR/>
<B>Settings: </B>acute bacterial meningitis<B> </B>
<BR/>
<B>Intervention:</B> cephalosporins versus conventional therapy for <I>H. influenzae</I> meningitis<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Cephalosporins versus conventional therapy for <I>H. influenzae</I> meningitis</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Death</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>318<BR/>(10)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>62 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>69 per 1000</B>
<BR/>(12 to 122)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>26 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>29 per 1000</B>
<BR/>(5 to 51)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2011-08-09 13:45:43 +1000" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2011-05-30 09:00:36 +1000" MODIFIED_BY="[Empty name]">Third generation cephalosporins versus conventional antibiotics for S. pneumoniae meningitis</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TD COLSPAN="7">
<P>
<B>Third generation cephalosporins versus conventional antibiotics for <I>S. pneumoniae</I> meningitis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients treated for <I>S. pneumoniae</I> meningitis<BR/>
<B>Settings: </B>acute bacterial meningitis<BR/>
<B>Intervention:</B> third generation cephalosporins versus conventional antibiotics for <I>S. pneumoniae</I> meningitis<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Third generation cephalosporins versus conventional antibiotics for <I>S. pneumoniae</I> meningitis</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Death</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>129<BR/>(11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>255 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>232 per 1000</B>
<BR/>(74 to 395)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>250 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>228 per 1000</B>
<BR/>(72 to 387)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2011-08-09 13:46:07 +1000" MODIFIED_BY="[Empty name]" NO="4" READONLY="YES">
<TITLE MODIFIED="2011-05-30 08:58:19 +1000" MODIFIED_BY="[Empty name]">Third generation cephalosporins versus conventional therapy for meningococcal meningitis</TITLE>
<TABLE COLS="7" ROWS="3">
<TR>
<TD COLSPAN="7">
<P>
<B>Third generation cephalosporins versus conventional therapy for meningococcal meningitis </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients treated for meningococcal meningitis<BR/>
<B>Settings: </B>acute bacterial meningitis<BR/>
<B>Intervention:</B> third generation cephalosporins versus conventional therapy for meningococcal meningitis<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Third generation cephalosporins versus conventional therapy for meningococcal meningitis</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Death</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>477<BR/>(13)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>39 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>35 per 1000</B>
<BR/>(-11 to 80)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2011-08-09 13:46:26 +1000" MODIFIED_BY="[Empty name]" NO="5" READONLY="YES">
<TITLE MODIFIED="2011-05-30 09:02:43 +1000" MODIFIED_BY="[Empty name]">Third generation cephalosporins versus conventional antibiotics (high and low/middle-income countries) for acute bacterial meningitis</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Third generation cephalosporins versus conventional antibiotics (high and low/middle-income countries) for acute bacterial meningitis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients treated for acute bacterial meningitis<BR/>
<B>Settings: </B>acute bacterial meningitis<BR/>
<B>Intervention:</B> third generation cephalosporins versus conventional antibiotics (high and low/middle-income countries)<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Third generation cephalosporins versus conventional antibiotics (high and low/middle-income countries)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Death</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1301<BR/>(19)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>67 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>62 per 1000</B>
<BR/>(37 to 87)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>44 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>40 per 1000</B>
<BR/>(24 to 57)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Death: high-income countries</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>510<BR/>(9)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>27 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>28 per 1000</B>
<BR/>(-3 to 66)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Death: Low/middle-income countries</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>791<BR/>(10)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>94 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>85 per 1000</B>
<BR/>(44 to 124)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>80 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>72 per 1000</B>
<BR/>(38 to 106)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Deafness</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>501<BR/>(10)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>114 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>76 per 1000</B>
<BR/>(24 to 124)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>54 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>36 per 1000</B>
<BR/>(11 to 59)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Deafness: high-income countries</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>380<BR/>(6)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>138 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>90 per 1000</B>
<BR/>(28 to 148)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>72 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>47 per 1000</B>
<BR/>(14 to 77)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Deafness: low-income countries</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>121<BR/>(4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>45 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>39 per 1000</B>
<BR/>(-44 to 124)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI)<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-08-09 13:46:39 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-08-09 13:46:39 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-05-30 08:38:35 +1000" MODIFIED_BY="[Empty name]">Income-based classification of countries where studies were conducted</TITLE>
<TABLE COLS="4" ROWS="10">
<TR>
<TH>
<P>High-income</P>
</TH>
<TH>
<P>Upper middle-income</P>
</TH>
<TH>
<P>Lower middle-income</P>
</TH>
<TH>
<P>Low-income</P>
</TH>
</TR>
<TR>
<TD>
<P>Arnoff 1984</P>
</TD>
<TD>
<P>Haffejee 1988</P>
</TD>
<TD>
<P>Bryan 1985</P>
</TD>
<TD>
<P>Nathan 2005</P>
</TD>
</TR>
<TR>
<TD>
<P>Barson 1985</P>
</TD>
<TD>
<P>Odio 1986</P>
</TD>
<TD>
<P>Filali 1993</P>
</TD>
<TD>
<P>Sharma 1996</P>
</TD>
</TR>
<TR>
<TD>
<P>Congeni 1984</P>
</TD>
<TD>
<P>Tuncer 1988</P>
</TD>
<TD>
<P>Girgis 1987</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Del Rio 1983</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Rodriguz 1985</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Jacobs 1985</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Girgis 1988</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Narciso 1983</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Peltola 1989</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Steele 1983</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Wells 1984</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-07-30 16:53:26 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-05-30 09:07:28 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Third generation cephalosporins versus conventional therapy</NAME>
<DICH_OUTCOME CHI2="3.2252795099756426" CI_END="0.02398673720209098" CI_START="-0.02776035253528115" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.0018868076665950865" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-1.6200288229574666" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2011-05-28 16:09:22 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9999518360740383" P_Q="1.0" P_Z="0.8863464022505121" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="750" TOTAL_2="746" WEIGHT="99.99999999999999" Z="0.1429288136221369">
<NAME>Death</NAME>
<GROUP_LABEL_1>3 g cephalosporins</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 g cephalo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.20805755281735927" CI_START="-0.20805755281735927" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20976" O_E="0.0" SE="0.10615376326222864" STUDY_ID="STD-Aronoff-1984" TOTAL_1="10" TOTAL_2="7" VAR="0.011268621454733284" WEIGHT="1.106924016096398"/>
<DICH_DATA CI_END="0.07530797045640844" CI_START="-0.07530797045640844" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20977" O_E="0.0" SE="0.03842313994054385" STUDY_ID="STD-Barson-1985" TOTAL_1="27" TOTAL_2="23" VAR="0.0014763376828906165" WEIGHT="3.3387990965513357"/>
<DICH_DATA CI_END="0.31348446402870445" CI_START="-0.2023733529175933" EFFECT_SIZE="0.05555555555555555" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20978" O_E="0.0" SE="0.13159880003288793" STUDY_ID="STD-Bryan-1985" TOTAL_1="18" TOTAL_2="18" VAR="0.017318244170096024" WEIGHT="2.4194196351821273"/>
<DICH_DATA CI_END="0.1936386737243876" CI_START="-0.0987770136453362" EFFECT_SIZE="0.047430830039525695" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20979" O_E="0.0" SE="0.07459720935595282" STUDY_ID="STD-Congeni-1984" TOTAL_1="22" TOTAL_2="23" VAR="0.005564743643695856" WEIGHT="3.0227810750670527"/>
<DICH_DATA CI_END="0.048691892198775316" CI_START="-0.048691892198775316" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20980" O_E="0.0" SE="0.02484325864293974" STUDY_ID="STD-Del-Rio-1983" TOTAL_1="39" TOTAL_2="39" VAR="6.171875E-4" WEIGHT="5.2420758762279425"/>
<DICH_DATA CI_END="0.16478692347043117" CI_START="-0.13978692347043115" EFFECT_SIZE="0.012499999999999997" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20981" O_E="0.0" SE="0.07769883766826889" STUDY_ID="STD-Filali-1993" TOTAL_1="16" TOTAL_2="20" VAR="0.006037109375" WEIGHT="2.3895502569700025"/>
<DICH_DATA CI_END="0.17852137291231943" CI_START="-0.17852137291231943" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20982" O_E="0.0" SE="0.09108400680852977" STUDY_ID="STD-Girgis-1987" TOTAL_1="15" TOTAL_2="15" VAR="0.008296296296296296" WEIGHT="2.0161830293184395"/>
<DICH_DATA CI_END="0.08677500150384146" CI_START="-0.20677500150384145" EFFECT_SIZE="-0.06" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20983" O_E="0.0" SE="0.07488658090739622" STUDY_ID="STD-Girgis-1988" TOTAL_1="50" TOTAL_2="50" VAR="0.005608" WEIGHT="6.720610097728132"/>
<DICH_DATA CI_END="0.18429815495132124" CI_START="-0.33429815495132126" EFFECT_SIZE="-0.07500000000000001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20984" O_E="0.0" SE="0.13229740801189818" STUDY_ID="STD-Haffejee-1988" TOTAL_1="16" TOTAL_2="15" VAR="0.017502604166666665" WEIGHT="2.0812211915545182"/>
<DICH_DATA CI_END="0.0640625336898663" CI_START="-0.13813660776394038" EFFECT_SIZE="-0.037037037037037035" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20985" O_E="0.0" SE="0.05158236147417189" STUDY_ID="STD-Jacobs-1985" TOTAL_1="23" TOTAL_2="27" VAR="0.0026607400152521324" WEIGHT="3.3387990965513357"/>
<DICH_DATA CI_END="0.31275377483746203" CI_START="-0.31275377483746203" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20986" O_E="0.0" SE="0.15957118462605635" STUDY_ID="STD-Narciso-1983" TOTAL_1="5" TOTAL_2="5" VAR="0.02546296296296296" WEIGHT="0.6720610097728131"/>
<DICH_DATA CI_END="0.04856045005939669" CI_START="-0.02895012617275701" EFFECT_SIZE="0.009805161943319839" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20987" O_E="0.0" SE="0.019773469523814525" STUDY_ID="STD-Nathan-2005" TOTAL_1="247" TOTAL_2="256" VAR="3.9099009700922175E-4" WEIGHT="33.793846337936"/>
<DICH_DATA CI_END="0.11058477996584293" CI_START="-0.10726252082963031" EFFECT_SIZE="0.0016611295681063093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20988" O_E="0.0" SE="0.055574312210281654" STUDY_ID="STD-Odio-1986" TOTAL_1="42" TOTAL_2="43" VAR="0.0030885041776458604" WEIGHT="5.711727923057414"/>
<DICH_DATA CI_END="0.06649523956231998" CI_START="-0.04829341938030177" EFFECT_SIZE="0.0091009100910091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20989" O_E="0.0" SE="0.029283359247430064" STUDY_ID="STD-Peltola-1989" TOTAL_1="101" TOTAL_2="99" VAR="8.575151288140479E-4" WEIGHT="13.439876073436716"/>
<DICH_DATA CI_END="0.15287456911596967" CI_START="-0.16968835642156024" EFFECT_SIZE="-0.008406893652795289" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20990" O_E="0.0" SE="0.08228797265711643" STUDY_ID="STD-Rodriguz-1985" TOTAL_1="61" TOTAL_2="39" VAR="0.006771310444018342" WEIGHT="6.39533256899809"/>
<DICH_DATA CI_END="0.1539830164746612" CI_START="-0.1539830164746612" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20991" O_E="0.0" SE="0.07856420714322282" STUDY_ID="STD-Sharma-1996" TOTAL_1="11" TOTAL_2="12" VAR="0.006172334644043224" WEIGHT="1.5428183180871535"/>
<DICH_DATA CI_END="0.12056853005506211" CI_START="-0.12056853005506211" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20992" O_E="0.0" SE="0.061515686515717274" STUDY_ID="STD-Steele-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.0037841796875" WEIGHT="2.0161830293184395"/>
<DICH_DATA CI_END="0.11256464966028347" CI_START="-0.1943828314784653" EFFECT_SIZE="-0.04090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20993" O_E="0.0" SE="0.078304367723058" STUDY_ID="STD-Tuncer-1988" TOTAL_1="20" TOTAL_2="22" VAR="0.006131574004507889" WEIGHT="2.81625566000036"/>
<DICH_DATA CI_END="0.10453735545339898" CI_START="-0.2156484665645101" EFFECT_SIZE="-0.05555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20994" O_E="0.0" SE="0.08168155755500968" STUDY_ID="STD-Wells-1984" TOTAL_1="12" TOTAL_2="18" VAR="0.006671876844612359" WEIGHT="1.9355357081457019"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.18254413108587" CI_END="0.014404322591090583" CI_START="-0.08632056825493709" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.035958122831923255" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-1.8415071609773876" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="2" P_CHI2="0.8181139063176274" P_Q="1.0" P_Z="0.1616965210220828" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="247" TOTAL_2="254" WEIGHT="99.99999999999999" Z="1.3993884750884575">
<NAME>Deafness</NAME>
<GROUP_LABEL_1>3 g cephalosporins</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 g cephalo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4158361404954409" CI_START="-0.30155042620972655" EFFECT_SIZE="0.05714285714285716" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20995" O_E="0.0" SE="0.18301014007497615" STUDY_ID="STD-Aronoff-1984" TOTAL_1="10" TOTAL_2="7" VAR="0.03349271137026239" WEIGHT="3.3130865180272693"/>
<DICH_DATA CI_END="0.09114354932265722" CI_START="-0.47209593027503816" EFFECT_SIZE="-0.19047619047619047" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20996" O_E="0.0" SE="0.14368618098099162" STUDY_ID="STD-Barson-1985" TOTAL_1="21" TOTAL_2="15" VAR="0.020645718604902278" WEIGHT="7.040308850807948"/>
<DICH_DATA CI_END="0.22766542754293492" CI_START="-0.2752844751619825" EFFECT_SIZE="-0.023809523809523808" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20997" O_E="0.0" SE="0.12830590425949714" STUDY_ID="STD-Bryan-1985" TOTAL_1="14" TOTAL_2="18" VAR="0.016462405067847245" WEIGHT="6.336277965727153"/>
<DICH_DATA CI_END="0.07769244897094243" CI_START="-0.4184331897116832" EFFECT_SIZE="-0.1703703703703704" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20998" O_E="0.0" SE="0.1265649885906071" STUDY_ID="STD-Del-Rio-1983" TOTAL_1="27" TOTAL_2="30" VAR="0.01601869633694051" WEIGHT="11.433885050936217"/>
<DICH_DATA CI_END="0.10931680180804859" CI_START="-0.10931680180804859" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="20999" O_E="0.0" SE="0.055774903350431726" STUDY_ID="STD-Filali-1993" TOTAL_1="15" TOTAL_2="19" VAR="0.00311083984375" WEIGHT="6.7444975545555135"/>
<DICH_DATA CI_END="0.13849245446348968" CI_START="-0.13849245446348968" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21000" O_E="0.0" SE="0.07066071394979728" STUDY_ID="STD-Haffejee-1988" TOTAL_1="14" TOTAL_2="12" VAR="0.004992936495895076" WEIGHT="5.198997305212023"/>
<DICH_DATA CI_END="0.0986044967412614" CI_START="-0.16549412884828482" EFFECT_SIZE="-0.03344481605351171" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21001" O_E="0.0" SE="0.06737333636554611" STUDY_ID="STD-Jacobs-1985" TOTAL_1="23" TOTAL_2="26" VAR="0.0045391664530250175" WEIGHT="9.81948616392572"/>
<DICH_DATA CI_END="0.05638329031243136" CI_START="-0.057260483294887504" EFFECT_SIZE="-4.3859649122807154E-4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21002" O_E="0.0" SE="0.028991291295076452" STUDY_ID="STD-Peltola-1989" TOTAL_1="96" TOTAL_2="95" VAR="8.404949709559757E-4" WEIGHT="38.41891800710156"/>
<DICH_DATA CI_END="0.17852137291231943" CI_START="-0.17852137291231943" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21003" O_E="0.0" SE="0.09108400680852977" STUDY_ID="STD-Steele-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.008296296296296296" WEIGHT="6.034550443549669"/>
<DICH_DATA CI_END="0.12919614117771058" CI_START="-0.12919614117771058" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21004" O_E="0.0" SE="0.06591760981160534" STUDY_ID="STD-Wells-1984" TOTAL_1="12" TOTAL_2="17" VAR="0.004345131283275048" WEIGHT="5.659992140156931"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.226227698075942" CI_END="-0.004229330014582165" CI_START="-0.11280596750664182" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.05851764876061199" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" I2="2.0151711167831983" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2011-05-30 09:07:28 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4245100476316189" P_Q="1.0" P_Z="0.03463031384717658" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="228" TOTAL_2="214" WEIGHT="100.00000000000001" Z="2.112654926141953">
<NAME>Culture positive 10 to 48 hours after start of treatment</NAME>
<GROUP_LABEL_1>3 g cephalosporins</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 g cephalo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.20805755281735927" CI_START="-0.20805755281735927" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21005" O_E="0.0" SE="0.10615376326222864" STUDY_ID="STD-Aronoff-1984" TOTAL_1="10" TOTAL_2="7" VAR="0.011268621454733284" WEIGHT="3.758934977360956"/>
<DICH_DATA CI_END="0.21910696578199845" CI_START="-0.35244029911533187" EFFECT_SIZE="-0.06666666666666671" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21006" O_E="0.0" SE="0.14580555290954889" STUDY_ID="STD-Barson-1985" TOTAL_1="24" TOTAL_2="20" VAR="0.02125925925925926" WEIGHT="9.958736823138118"/>
<DICH_DATA CI_END="0.23032575441633055" CI_START="-0.21561987206338937" EFFECT_SIZE="0.00735294117647059" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21007" O_E="0.0" SE="0.11376372984332418" STUDY_ID="STD-Bryan-1985" TOTAL_1="16" TOTAL_2="17" VAR="0.012942186227864848" WEIGHT="7.524378933037689"/>
<DICH_DATA CI_END="-0.010785495885733548" CI_START="-0.3701668850666474" EFFECT_SIZE="-0.19047619047619047" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21008" O_E="0.0" SE="0.09168061046418922" STUDY_ID="STD-Congeni-1984" TOTAL_1="21" TOTAL_2="21" VAR="0.008405334335086402" WEIGHT="9.58528419227044"/>
<DICH_DATA CI_END="0.14121211079003348" CI_START="-0.13594895289529668" EFFECT_SIZE="0.0026315789473684154" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21009" O_E="0.0" SE="0.07070565221390324" STUDY_ID="STD-Del-Rio-1983" TOTAL_1="19" TOTAL_2="20" VAR="0.004999289254993439" WEIGHT="8.89476921382849"/>
<DICH_DATA CI_END="0.10345213352519027" CI_START="-0.10345213352519027" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21010" O_E="0.0" SE="0.052782670672118205" STUDY_ID="STD-Filali-1993" TOTAL_1="16" TOTAL_2="20" VAR="0.0027860103232812874" WEIGHT="8.114526300334763"/>
<DICH_DATA CI_END="0.12846807114502387" CI_START="-0.12846807114502387" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21011" O_E="0.0" SE="0.06554613868334501" STUDY_ID="STD-Girgis-1988" TOTAL_1="14" TOTAL_2="14" VAR="0.004296296296296296" WEIGHT="6.390189461513626"/>
<DICH_DATA CI_END="0.25511215125292974" CI_START="-0.3416506127913913" EFFECT_SIZE="-0.04326923076923078" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21012" O_E="0.0" SE="0.1522381964034823" STUDY_ID="STD-Haffejee-1988" TOTAL_1="16" TOTAL_2="13" VAR="0.023176468444185253" WEIGHT="6.547583290614947"/>
<DICH_DATA CI_END="0.10263290926445989" CI_START="-0.10263290926445989" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21013" O_E="0.0" SE="0.05236469143005442" STUDY_ID="STD-Jacobs-1985" TOTAL_1="23" TOTAL_2="15" VAR="0.0027420609085648147" WEIGHT="8.288027685045869"/>
<DICH_DATA CI_END="-0.047154421595794915" CI_START="-0.2784269737530423" EFFECT_SIZE="-0.16279069767441862" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21014" O_E="0.0" SE="0.05899918416396826" STUDY_ID="STD-Odio-1986" TOTAL_1="42" TOTAL_2="43" VAR="0.0034809037320138432" WEIGHT="19.396104483182533"/>
<DICH_DATA CI_END="0.12056853005506211" CI_START="-0.12056853005506211" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21015" O_E="0.0" SE="0.061515686515717274" STUDY_ID="STD-Steele-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.0037841796875" WEIGHT="6.846631565907456"/>
<DICH_DATA CI_END="0.17080710374500646" CI_START="-0.17080710374500646" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21016" O_E="0.0" SE="0.08714808286902774" STUDY_ID="STD-Wells-1984" TOTAL_1="12" TOTAL_2="9" VAR="0.0075947883477469275" WEIGHT="4.694833073765113"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="27.034534213679713" CI_END="0.1276454683556473" CI_START="0.027230525124953477" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RD" EFFECT_SIZE="0.07743799674030039" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="45" I2="59.31130193308859" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.8939945988234669" LOG_CI_START="-1.5649439834609682" LOG_EFFECT_SIZE="-1.11104589040894" METHOD="MH" MODIFIED="2008-07-01 09:09:49 +1000" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="0.0045403608885257185" P_Q="1.0" P_Z="0.002503069872281658" Q="0.0" RANDOM="NO" SCALE="0.8547914661503855" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="389" TOTAL_2="361" WEIGHT="100.00000000000001" Z="3.0229700831922717">
<NAME>Diarrhoea</NAME>
<GROUP_LABEL_1>3 g cephalosporins</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 g cephalo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.20805755281735927" CI_START="-0.20805755281735927" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21017" O_E="0.0" SE="0.10615376326222864" STUDY_ID="STD-Aronoff-1984" TOTAL_1="10" TOTAL_2="7" VAR="0.011268621454733284" WEIGHT="2.2144986723719233"/>
<DICH_DATA CI_END="0.6257302602831198" CI_START="0.12467231620641323" EFFECT_SIZE="0.3752012882447665" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21018" O_E="0.0" SE="0.12782325288346819" STUDY_ID="STD-Barson-1985" TOTAL_1="27" TOTAL_2="23" VAR="0.016338783977711057" WEIGHT="6.679560709780113"/>
<DICH_DATA CI_END="0.20531908508884117" CI_START="-0.20531908508884117" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21019" O_E="0.0" SE="0.10475656017578482" STUDY_ID="STD-Bryan-1985" TOTAL_1="18" TOTAL_2="18" VAR="0.010973936899862825" WEIGHT="4.840261383898633"/>
<DICH_DATA CI_END="0.349901157928559" CI_START="-0.06926874686136536" EFFECT_SIZE="0.14031620553359683" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21020" O_E="0.0" SE="0.10693306308082268" STUDY_ID="STD-Congeni-1984" TOTAL_1="22" TOTAL_2="23" VAR="0.011434679979847201" WEIGHT="6.047338914204217"/>
<DICH_DATA CI_END="0.4048573932106839" CI_START="0.00539901704572629" EFFECT_SIZE="0.20512820512820512" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21021" O_E="0.0" SE="0.10190451950031591" STUDY_ID="STD-Del-Rio-1983" TOTAL_1="39" TOTAL_2="39" VAR="0.010384531094590267" WEIGHT="10.487232998447038"/>
<DICH_DATA CI_END="0.3499868417762432" CI_START="-0.10832017510957652" EFFECT_SIZE="0.12083333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21022" O_E="0.0" SE="0.1169172037090699" STUDY_ID="STD-Haffejee-1988" TOTAL_1="16" TOTAL_2="15" VAR="0.013669632523148147" WEIGHT="4.163665706579469"/>
<DICH_DATA CI_END="0.21864702732650484" CI_START="-0.04473398384824398" EFFECT_SIZE="0.08695652173913043" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21023" O_E="0.0" SE="0.06719026809988975" STUDY_ID="STD-Jacobs-1985" TOTAL_1="23" TOTAL_2="27" VAR="0.004514532127335061" WEIGHT="6.679560709780113"/>
<DICH_DATA CI_END="0.006525464547016052" CI_START="-0.28227297285266395" EFFECT_SIZE="-0.13787375415282394" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21024" O_E="0.0" SE="0.07367442455006448" STUDY_ID="STD-Odio-1986" TOTAL_1="42" TOTAL_2="43" VAR="0.005427920832783144" WEIGHT="11.426813149439125"/>
<DICH_DATA CI_END="0.19700192846266798" CI_START="-0.025184746744496195" EFFECT_SIZE="0.08590859085908589" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21025" O_E="0.0" SE="0.05668131582002126" STUDY_ID="STD-Peltola-1989" TOTAL_1="101" TOTAL_2="99" VAR="0.0032127715630889927" WEIGHT="26.887651987556904"/>
<DICH_DATA CI_END="0.049712599971290725" CI_START="-0.06820776600744037" EFFECT_SIZE="-0.00924758301807482" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21026" O_E="0.0" SE="0.03008227878391437" STUDY_ID="STD-Rodriguz-1985" TOTAL_1="61" TOTAL_2="39" VAR="9.049434968331447E-4" WEIGHT="12.794424258105385"/>
<DICH_DATA CI_END="0.37189255249562103" CI_START="-0.10522588582895429" EFFECT_SIZE="0.13333333333333336" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21027" O_E="0.0" SE="0.12171612389003691" STUDY_ID="STD-Steele-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.014814814814814815" WEIGHT="4.033551153248861"/>
<DICH_DATA CI_END="0.12929825184848712" CI_START="-0.12929825184848712" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21028" O_E="0.0" SE="0.06596970804993113" STUDY_ID="STD-Tuncer-1988" TOTAL_1="15" TOTAL_2="13" VAR="0.0043520023801931484" WEIGHT="3.7454403565882277"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1103092659045024" CI_END="0.016519976745313608" CI_START="-0.06560504012792756" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.024542531691306976" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-1.7819905683588015" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2008-07-01 09:09:49 +1000" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="0.9597603685318253" P_Q="1.0" P_Z="0.2414198953219301" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="249" TOTAL_2="223" WEIGHT="100.0" Z="1.1714451950406315">
<NAME>Neutropenia</NAME>
<GROUP_LABEL_1>3 g cephalosporins</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 g cephalo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.20805755281735927" CI_START="-0.20805755281735927" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21029" O_E="0.0" SE="0.10615376326222864" STUDY_ID="STD-Aronoff-1984" TOTAL_1="10" TOTAL_2="7" VAR="0.011268621454733284" WEIGHT="3.5361191302834425"/>
<DICH_DATA CI_END="0.08388261590625026" CI_START="-0.2835605547146238" EFFECT_SIZE="-0.0998389694041868" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21030" O_E="0.0" SE="0.0937372251529158" STUDY_ID="STD-Barson-1985" TOTAL_1="27" TOTAL_2="23" VAR="0.00878666737936843" WEIGHT="10.665945616686374"/>
<DICH_DATA CI_END="0.12409864389718048" CI_START="-0.23520975500829158" EFFECT_SIZE="-0.05555555555555555" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21031" O_E="0.0" SE="0.09166199015381171" STUDY_ID="STD-Bryan-1985" TOTAL_1="18" TOTAL_2="18" VAR="0.008401920438957475" WEIGHT="7.7289460990480965"/>
<DICH_DATA CI_END="0.16141724157018283" CI_START="-0.07050815066109194" EFFECT_SIZE="0.045454545454545456" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21032" O_E="0.0" SE="0.05916572805946249" STUDY_ID="STD-Congeni-1984" TOTAL_1="22" TOTAL_2="23" VAR="0.003500583376806267" WEIGHT="9.656411669427992"/>
<DICH_DATA CI_END="0.138119539117722" CI_START="-0.2797862057843887" EFFECT_SIZE="-0.07083333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21033" O_E="0.0" SE="0.10661056738758923" STUDY_ID="STD-Haffejee-1988" TOTAL_1="16" TOTAL_2="15" VAR="0.011365813078703704" WEIGHT="6.648555784127395"/>
<DICH_DATA CI_END="0.07530797045640844" CI_START="-0.07530797045640844" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21034" O_E="0.0" SE="0.03842313994054385" STUDY_ID="STD-Jacobs-1985" TOTAL_1="23" TOTAL_2="27" VAR="0.0014763376828906165" WEIGHT="10.665945616686374"/>
<DICH_DATA CI_END="0.07758080711534672" CI_START="-0.12187759559818172" EFFECT_SIZE="-0.0221483942414175" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21035" O_E="0.0" SE="0.05088318058056956" STUDY_ID="STD-Odio-1986" TOTAL_1="42" TOTAL_2="43" VAR="0.002589098065994851" WEIGHT="18.246374712262565"/>
<DICH_DATA CI_END="0.03730304657306196" CI_START="-0.08858509785511323" EFFECT_SIZE="-0.02564102564102564" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21036" O_E="0.0" SE="0.032114912677264684" STUDY_ID="STD-Rodriguz-1985" TOTAL_1="61" TOTAL_2="39" VAR="0.001031367616268336" WEIGHT="20.430180855150468"/>
<DICH_DATA CI_END="0.12056853005506211" CI_START="-0.12056853005506211" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21037" O_E="0.0" SE="0.061515686515717274" STUDY_ID="STD-Steele-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.0037841796875" WEIGHT="6.440788415873414"/>
<DICH_DATA CI_END="0.12929825184848712" CI_START="-0.12929825184848712" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21038" O_E="0.0" SE="0.06596970804993113" STUDY_ID="STD-Tuncer-1988" TOTAL_1="15" TOTAL_2="13" VAR="0.0043520023801931484" WEIGHT="5.980732100453885"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5167716938650075" CI_END="0.014944332291752082" CI_START="-0.038413363788160654" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.011734515748204284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-1.825523484337357" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2008-07-01 09:09:49 +1000" MODIFIED_BY="Liz Dooley" NO="6" P_CHI2="0.8334458810347006" P_Q="1.0" P_Z="0.38864501238972626" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="285" TOTAL_2="248" WEIGHT="100.0" Z="0.8620772609092046">
<NAME>Skin rash</NAME>
<GROUP_LABEL_1>3 g cephalosporins</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 g cephalo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.20805755281735927" CI_START="-0.20805755281735927" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21039" O_E="0.0" SE="0.10615376326222864" STUDY_ID="STD-Aronoff-1984" TOTAL_1="10" TOTAL_2="7" VAR="0.011268621454733284" WEIGHT="3.127661915182981"/>
<DICH_DATA CI_END="0.07530797045640844" CI_START="-0.07530797045640844" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21040" O_E="0.0" SE="0.03842313994054385" STUDY_ID="STD-Barson-1985" TOTAL_1="27" TOTAL_2="23" VAR="0.0014763376828906165" WEIGHT="9.433921953881924"/>
<DICH_DATA CI_END="0.10178963423348945" CI_START="-0.10178963423348945" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21041" O_E="0.0" SE="0.051934441161364746" STUDY_ID="STD-Bryan-1985" TOTAL_1="18" TOTAL_2="18" VAR="0.002697186178743257" WEIGHT="6.836175328899945"/>
<DICH_DATA CI_END="0.11712827820384197" CI_START="-0.11712827820384197" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21042" O_E="0.0" SE="0.059760423726014804" STUDY_ID="STD-Haffejee-1988" TOTAL_1="16" TOTAL_2="15" VAR="0.003571308243912833" WEIGHT="5.880580928085974"/>
<DICH_DATA CI_END="0.08696416105822835" CI_START="-0.039345113439180734" EFFECT_SIZE="0.023809523809523808" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21043" O_E="0.0" SE="0.03222234579148406" STUDY_ID="STD-Odio-1986" TOTAL_1="42" TOTAL_2="43" VAR="0.0010382795683059702" WEIGHT="16.138735482344185"/>
<DICH_DATA CI_END="0.002330084072358324" CI_START="-0.08566341740569165" EFFECT_SIZE="-0.041666666666666664" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21044" O_E="0.0" SE="0.022447734288010262" STUDY_ID="STD-Peltola-1989" TOTAL_1="101" TOTAL_2="96" VAR="5.039007746651115E-4" WEIGHT="37.384972357029824"/>
<DICH_DATA CI_END="0.041001098181696755" CI_START="-0.041001098181696755" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21045" O_E="0.0" SE="0.020919312040990644" STUDY_ID="STD-Rodriguz-1985" TOTAL_1="61" TOTAL_2="39" VAR="4.3761761626833607E-4" WEIGHT="18.070290119392187"/>
<DICH_DATA CI_END="0.20805755281735927" CI_START="-0.20805755281735927" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21046" O_E="0.0" SE="0.10615376326222864" STUDY_ID="STD-Steele-1983" TOTAL_1="10" TOTAL_2="7" VAR="0.011268621454733284" WEIGHT="3.127661915182981"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.844521787503645" CI_END="0.020350632329860112" CI_START="-0.0361675809581791" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.007908474314159494" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-1.6914220919374086" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2008-07-01 09:09:49 +1000" MODIFIED_BY="Liz Dooley" NO="7" P_CHI2="0.9967872026489237" P_Q="1.0" P_Z="0.5833436560083949" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="750" TOTAL_2="746" WEIGHT="99.99999999999997" Z="0.5485072484304101">
<NAME>Treatment failure (either death or deafness)</NAME>
<GROUP_LABEL_1>3 g cephalosporins</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 g cephalo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.20805755281735927" CI_START="-0.20805755281735927" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21047" O_E="0.0" SE="0.10615376326222864" STUDY_ID="STD-Aronoff-1984" TOTAL_1="10" TOTAL_2="7" VAR="0.011268621454733284" WEIGHT="1.106924016096398"/>
<DICH_DATA CI_END="0.0997961707379672" CI_START="-0.31235655721139716" EFFECT_SIZE="-0.10628019323671498" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21048" O_E="0.0" SE="0.10514293405398581" STUDY_ID="STD-Barson-1985" TOTAL_1="27" TOTAL_2="23" VAR="0.011055036581480809" WEIGHT="3.3387990965513357"/>
<DICH_DATA CI_END="0.3079786276332617" CI_START="-0.3079786276332617" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21049" O_E="0.0" SE="0.15713484026367722" STUDY_ID="STD-Bryan-1985" TOTAL_1="18" TOTAL_2="18" VAR="0.024691358024691357" WEIGHT="2.4194196351821273"/>
<DICH_DATA CI_END="0.1936386737243876" CI_START="-0.0987770136453362" EFFECT_SIZE="0.047430830039525695" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21050" O_E="0.0" SE="0.07459720935595282" STUDY_ID="STD-Congeni-1984" TOTAL_1="22" TOTAL_2="23" VAR="0.005564743643695856" WEIGHT="3.0227810750670527"/>
<DICH_DATA CI_END="0.09384488580072844" CI_START="-0.04256283451867716" EFFECT_SIZE="0.02564102564102564" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21051" O_E="0.0" SE="0.03479852726768764" STUDY_ID="STD-Del-Rio-1983" TOTAL_1="39" TOTAL_2="39" VAR="0.0012109375" WEIGHT="5.2420758762279425"/>
<DICH_DATA CI_END="0.16478692347043117" CI_START="-0.13978692347043115" EFFECT_SIZE="0.012499999999999997" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21052" O_E="0.0" SE="0.07769883766826889" STUDY_ID="STD-Filali-1993" TOTAL_1="16" TOTAL_2="20" VAR="0.006037109375" WEIGHT="2.3895502569700025"/>
<DICH_DATA CI_END="0.17852137291231943" CI_START="-0.17852137291231943" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21053" O_E="0.0" SE="0.09108400680852977" STUDY_ID="STD-Girgis-1987" TOTAL_1="15" TOTAL_2="15" VAR="0.008296296296296296" WEIGHT="2.0161830293184395"/>
<DICH_DATA CI_END="0.08677500150384146" CI_START="-0.20677500150384145" EFFECT_SIZE="-0.06" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21054" O_E="0.0" SE="0.07488658090739622" STUDY_ID="STD-Girgis-1988" TOTAL_1="50" TOTAL_2="50" VAR="0.005608" WEIGHT="6.720610097728132"/>
<DICH_DATA CI_END="0.18429815495132124" CI_START="-0.33429815495132126" EFFECT_SIZE="-0.07500000000000001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21055" O_E="0.0" SE="0.13229740801189818" STUDY_ID="STD-Haffejee-1988" TOTAL_1="16" TOTAL_2="15" VAR="0.017502604166666665" WEIGHT="2.0812211915545182"/>
<DICH_DATA CI_END="0.07727396387362792" CI_START="-0.2125396643567197" EFFECT_SIZE="-0.06763285024154589" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21056" O_E="0.0" SE="0.07393340656164106" STUDY_ID="STD-Jacobs-1985" TOTAL_1="23" TOTAL_2="27" VAR="0.005466148605808909" WEIGHT="3.3387990965513357"/>
<DICH_DATA CI_END="0.31275377483746203" CI_START="-0.31275377483746203" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21057" O_E="0.0" SE="0.15957118462605635" STUDY_ID="STD-Narciso-1983" TOTAL_1="5" TOTAL_2="5" VAR="0.02546296296296296" WEIGHT="0.6720610097728131"/>
<DICH_DATA CI_END="0.04856045005939669" CI_START="-0.02895012617275701" EFFECT_SIZE="0.009805161943319839" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21058" O_E="0.0" SE="0.019773469523814525" STUDY_ID="STD-Nathan-2005" TOTAL_1="247" TOTAL_2="256" VAR="3.9099009700922175E-4" WEIGHT="33.793846337936"/>
<DICH_DATA CI_END="0.11058477996584293" CI_START="-0.10726252082963031" EFFECT_SIZE="0.0016611295681063093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21059" O_E="0.0" SE="0.055574312210281654" STUDY_ID="STD-Odio-1986" TOTAL_1="42" TOTAL_2="43" VAR="0.0030885041776458604" WEIGHT="5.711727923057414"/>
<DICH_DATA CI_END="0.08556252168364044" CI_START="-0.06896086151762386" EFFECT_SIZE="0.00830083008300829" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21060" O_E="0.0" SE="0.039419954759405025" STUDY_ID="STD-Peltola-1989" TOTAL_1="101" TOTAL_2="99" VAR="0.001553932833233539" WEIGHT="13.439876073436716"/>
<DICH_DATA CI_END="0.15287456911596967" CI_START="-0.16968835642156024" EFFECT_SIZE="-0.008406893652795289" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21061" O_E="0.0" SE="0.08228797265711643" STUDY_ID="STD-Rodriguz-1985" TOTAL_1="61" TOTAL_2="39" VAR="0.006771310444018342" WEIGHT="6.39533256899809"/>
<DICH_DATA CI_END="0.1539830164746612" CI_START="-0.1539830164746612" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21062" O_E="0.0" SE="0.07856420714322282" STUDY_ID="STD-Sharma-1996" TOTAL_1="11" TOTAL_2="12" VAR="0.006172334644043224" WEIGHT="1.5428183180871535"/>
<DICH_DATA CI_END="0.09966660313580787" CI_START="-0.2329999364691412" EFFECT_SIZE="-0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21063" O_E="0.0" SE="0.08486547258750168" STUDY_ID="STD-Steele-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.0072021484375" WEIGHT="2.0161830293184395"/>
<DICH_DATA CI_END="0.11256464966028347" CI_START="-0.1943828314784653" EFFECT_SIZE="-0.04090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21064" O_E="0.0" SE="0.078304367723058" STUDY_ID="STD-Tuncer-1988" TOTAL_1="20" TOTAL_2="22" VAR="0.006131574004507889" WEIGHT="2.81625566000036"/>
<DICH_DATA CI_END="0.10453735545339898" CI_START="-0.2156484665645101" EFFECT_SIZE="-0.05555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21065" O_E="0.0" SE="0.08168155755500968" STUDY_ID="STD-Wells-1984" TOTAL_1="12" TOTAL_2="18" VAR="0.006671876844612359" WEIGHT="1.9355357081457019"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Cephalosporins versus conventional therapy for H. influenzae meningitis</NAME>
<DICH_OUTCOME CHI2="1.1062326070692012" CI_END="0.06481140089810743" CI_START="-0.04976935721514302" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0075210218414822" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-1.1883485911723326" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.123723150104009" METHOD="MH" NO="1" P_CHI2="0.9991511201492198" P_Q="1.0" P_Z="0.7969456108481826" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="157" TOTAL_2="161" WEIGHT="100.0" Z="0.2573020492965223">
<NAME>Death</NAME>
<GROUP_LABEL_1>3 g cephalosporins</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 g cephalo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.494501060745322" CI_START="-0.36751693376119504" EFFECT_SIZE="0.06349206349206349" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21066" O_E="0.0" SE="0.21990659045421368" STUDY_ID="STD-Bryan-1985" TOTAL_1="7" TOTAL_2="9" VAR="0.04835890852519727" WEIGHT="5.056433007293774"/>
<DICH_DATA CI_END="0.1212545709944118" CI_START="-0.1212545709944118" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21067" O_E="0.0" SE="0.06186571383497471" STUDY_ID="STD-Congeni-1984" TOTAL_1="14" TOTAL_2="16" VAR="0.0038273665483109813" WEIGHT="9.588495184201527"/>
<DICH_DATA CI_END="0.2337639657721092" CI_START="-0.2337639657721092" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21068" O_E="0.0" SE="0.1192695210810043" STUDY_ID="STD-Del-Rio-1983" TOTAL_1="6" TOTAL_2="9" VAR="0.01422521865889213" WEIGHT="4.623024463811451"/>
<DICH_DATA CI_END="0.5045862103576256" CI_START="-0.4474433532147686" EFFECT_SIZE="0.028571428571428525" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21069" O_E="0.0" SE="0.2428691473623704" STUDY_ID="STD-Girgis-1987" TOTAL_1="7" TOTAL_2="10" VAR="0.05898542274052478" WEIGHT="5.2877730795229"/>
<DICH_DATA CI_END="0.1025976062181481" CI_START="-0.23593093955148142" EFFECT_SIZE="-0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21070" O_E="0.0" SE="0.0863609098023993" STUDY_ID="STD-Jacobs-1985" TOTAL_1="14" TOTAL_2="15" VAR="0.007458206741898148" WEIGHT="9.299187139850618"/>
<DICH_DATA CI_END="0.1161866985498215" CI_START="-0.09753867990180284" EFFECT_SIZE="0.009324009324009327" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21071" O_E="0.0" SE="0.054522782086166593" STUDY_ID="STD-Odio-1986" TOTAL_1="33" TOTAL_2="39" VAR="0.002972733766415609" WEIGHT="22.95460063628602"/>
<DICH_DATA CI_END="0.10449033407339156" CI_START="-0.04893477851783601" EFFECT_SIZE="0.027777777777777776" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21072" O_E="0.0" SE="0.03913977853711223" STUDY_ID="STD-Peltola-1989" TOTAL_1="36" TOTAL_2="31" VAR="0.0015319222639341914" WEIGHT="21.390113190769398"/>
<DICH_DATA CI_END="0.1676985695449012" CI_START="-0.15288375473008636" EFFECT_SIZE="0.007407407407407404" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21073" O_E="0.0" SE="0.0817827079486409" STUDY_ID="STD-Rodriguz-1985" TOTAL_1="27" TOTAL_2="15" VAR="0.006688411319412691" WEIGHT="12.383101242352097"/>
<DICH_DATA CI_END="0.22479106028080592" CI_START="-0.22479106028080592" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21074" O_E="0.0" SE="0.11469142395162825" STUDY_ID="STD-Sharma-1996" TOTAL_1="7" TOTAL_2="8" VAR="0.013154122728052126" WEIGHT="4.7942475921007635"/>
<DICH_DATA CI_END="0.2337639657721092" CI_START="-0.2337639657721092" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21075" O_E="0.0" SE="0.1192695210810043" STUDY_ID="STD-Steele-1983" TOTAL_1="6" TOTAL_2="9" VAR="0.01422521865889213" WEIGHT="4.623024463811451"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-07-30 16:52:40 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Third generation cephalosporins versus conventional antibiotics for S. pneumoniae meningitis</NAME>
<DICH_OUTCOME CHI2="0.7875106280026395" CI_END="0.13644897731260386" CI_START="-0.1835601837116198" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.023555603199507977" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.8650297150263844" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2008-06-28 12:29:26 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9999430978365256" P_Q="1.0" P_Z="0.7729314447146155" Q="0.0" RANDOM="NO" SCALE="1.662880785055271" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="55" WEIGHT="100.00000000000001" Z="0.28854257645241177">
<NAME>Death</NAME>
<GROUP_LABEL_1>3 g cephalosporins</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 g cephalo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0411578660639893" CI_START="-0.7078245327306558" EFFECT_SIZE="0.16666666666666669" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21076" O_E="0.0" SE="0.44617717789469474" STUDY_ID="STD-Bryan-1985" TOTAL_1="2" TOTAL_2="3" VAR="0.19907407407407407" WEIGHT="4.02028332992246"/>
<DICH_DATA CI_END="0.7543904893841146" CI_START="-0.7543904893841146" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21077" O_E="0.0" SE="0.3849001794597505" STUDY_ID="STD-Congeni-1984" TOTAL_1="3" TOTAL_2="3" VAR="0.14814814814814814" WEIGHT="5.025354162403075"/>
<DICH_DATA CI_END="0.8486893005571289" CI_START="-0.8486893005571289" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21078" O_E="0.0" SE="0.4330127018922193" STUDY_ID="STD-Filali-1993" TOTAL_1="1" TOTAL_2="1" VAR="0.1875" WEIGHT="1.6751180541343584"/>
<DICH_DATA CI_END="0.2464337069264524" CI_START="-0.33140102718789033" EFFECT_SIZE="-0.04248366013071897" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21079" O_E="0.0" SE="0.1474095286118085" STUDY_ID="STD-Girgis-1987" TOTAL_1="17" TOTAL_2="18" VAR="0.021729569125555587" WEIGHT="29.290635689435064"/>
<DICH_DATA CI_END="0.2627843410086203" CI_START="-0.41663049485477416" EFFECT_SIZE="-0.07692307692307693" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21080" O_E="0.0" SE="0.1733232960458794" STUDY_ID="STD-Girgis-1988" TOTAL_1="13" TOTAL_2="13" VAR="0.030040964952207556" WEIGHT="21.77653470374666"/>
<DICH_DATA CI_END="0.3923612512288847" CI_START="-0.3923612512288847" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21081" O_E="0.0" SE="0.20018799035277188" STUDY_ID="STD-Jacobs-1985" TOTAL_1="5" TOTAL_2="3" VAR="0.04007523148148148" WEIGHT="6.281692703003844"/>
<DICH_DATA CI_END="0.332517845176033" CI_START="-0.6102956229538108" EFFECT_SIZE="-0.1388888888888889" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21082" O_E="0.0" SE="0.2405180594048248" STUDY_ID="STD-Odio-1986" TOTAL_1="9" TOTAL_2="4" VAR="0.05784893689986283" WEIGHT="9.277576915205676"/>
<DICH_DATA CI_END="0.629710589664237" CI_START="-0.629710589664237" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21083" O_E="0.0" SE="0.3212868168146526" STUDY_ID="STD-Peltola-1989" TOTAL_1="6" TOTAL_2="1" VAR="0.10322521865889213" WEIGHT="2.871630949944614"/>
<DICH_DATA CI_END="0.6142182566684231" CI_START="-0.41421825666842316" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21084" O_E="0.0" SE="0.26236107434856515" STUDY_ID="STD-Rodriguz-1985" TOTAL_1="12" TOTAL_2="5" VAR="0.06883333333333333" WEIGHT="11.824362735066059"/>
<DICH_DATA CI_END="0.8486893005571289" CI_START="-0.8486893005571289" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21085" O_E="0.0" SE="0.4330127018922193" STUDY_ID="STD-Sharma-1996" TOTAL_1="1" TOTAL_2="1" VAR="0.1875" WEIGHT="1.6751180541343584"/>
<DICH_DATA CI_END="0.3923612512288847" CI_START="-0.3923612512288847" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21086" O_E="0.0" SE="0.20018799035277188" STUDY_ID="STD-Steele-1983" TOTAL_1="5" TOTAL_2="3" VAR="0.04007523148148148" WEIGHT="6.281692703003844"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Third generation cephalosporins versus conventional therapy for meningococcal meningitis</NAME>
<DICH_OUTCOME CHI2="1.9228599861637168" CI_END="0.03808985351498108" CI_START="-0.04589962392283779" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.0039048852039283597" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-1.419190697534846" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.9995152550813411" P_Q="1.0" P_Z="0.8553885308891189" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="244" TOTAL_2="233" WEIGHT="100.0" Z="0.1822474575848887">
<NAME>Death</NAME>
<GROUP_LABEL_1>3 g cephalosporins</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 g cephalo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7334726172209501" CI_START="-0.7334726172209501" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21087" O_E="0.0" SE="0.3742275995918744" STUDY_ID="STD-Barson-1985" TOTAL_1="2" TOTAL_2="1" VAR="0.14004629629629628" WEIGHT="0.5676941787945733"/>
<DICH_DATA CI_END="0.7334726172209501" CI_START="-0.7334726172209501" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21088" O_E="0.0" SE="0.3742275995918744" STUDY_ID="STD-Bryan-1985" TOTAL_1="1" TOTAL_2="2" VAR="0.14004629629629628" WEIGHT="0.5676941787945733"/>
<DICH_DATA CI_END="0.6820386015970279" CI_START="-0.6820386015970279" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21089" O_E="0.0" SE="0.34798527267687634" STUDY_ID="STD-Congeni-1984" TOTAL_1="3" TOTAL_2="1" VAR="0.12109375" WEIGHT="0.638655951143895"/>
<DICH_DATA CI_END="0.16478692347043117" CI_START="-0.13978692347043115" EFFECT_SIZE="0.012499999999999997" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21090" O_E="0.0" SE="0.07769883766826889" STUDY_ID="STD-Filali-1993" TOTAL_1="16" TOTAL_2="20" VAR="0.006037109375" WEIGHT="7.569255717260978"/>
<DICH_DATA CI_END="0.06754179025226739" CI_START="-0.1584508811613583" EFFECT_SIZE="-0.045454545454545456" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21091" O_E="0.0" SE="0.057652251060791686" STUDY_ID="STD-Girgis-1987" TOTAL_1="26" TOTAL_2="22" VAR="0.003323782052376556" WEIGHT="10.147533445952996"/>
<DICH_DATA CI_END="0.16713734661541962" CI_START="-0.16713734661541962" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21092" O_E="0.0" SE="0.08527572339786735" STUDY_ID="STD-Girgis-1988" TOTAL_1="11" TOTAL_2="10" VAR="0.00727194900102958" WEIGHT="4.460454261957362"/>
<DICH_DATA CI_END="0.3923612512288847" CI_START="-0.3923612512288847" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21093" O_E="0.0" SE="0.20018799035277188" STUDY_ID="STD-Jacobs-1985" TOTAL_1="3" TOTAL_2="5" VAR="0.04007523148148148" WEIGHT="1.5966398778597375"/>
<DICH_DATA CI_END="0.7334726172209501" CI_START="-0.7334726172209501" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21094" O_E="0.0" SE="0.3742275995918744" STUDY_ID="STD-Narciso-1983" TOTAL_1="1" TOTAL_2="2" VAR="0.14004629629629628" WEIGHT="0.5676941787945733"/>
<DICH_DATA CI_END="0.04511476473603136" CI_START="-0.03768233230359894" EFFECT_SIZE="0.003716216216216213" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21095" O_E="0.0" SE="0.021122096551957903" STUDY_ID="STD-Nathan-2005" TOTAL_1="160" TOTAL_2="148" VAR="4.46142962750232E-4" WEIGHT="65.46914685319234"/>
<DICH_DATA CI_END="0.8486893005571289" CI_START="-0.8486893005571289" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21096" O_E="0.0" SE="0.4330127018922193" STUDY_ID="STD-Peltola-1989" TOTAL_1="1" TOTAL_2="1" VAR="0.1875" WEIGHT="0.42577063409592997"/>
<DICH_DATA CI_END="0.1576468180344909" CI_START="-0.49098015136782425" EFFECT_SIZE="-0.16666666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21097" O_E="0.0" SE="0.16546910415665844" STUDY_ID="STD-Rodriguz-1985" TOTAL_1="11" TOTAL_2="6" VAR="0.027380024430407084" WEIGHT="3.3059837470978093"/>
<DICH_DATA CI_END="0.4583446075353238" CI_START="-0.4583446075353238" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21098" O_E="0.0" SE="0.23385358667337133" STUDY_ID="STD-Sharma-1996" TOTAL_1="3" TOTAL_2="3" VAR="0.0546875" WEIGHT="1.27731190228779"/>
<DICH_DATA CI_END="0.4200474387777126" CI_START="-0.253380772111046" EFFECT_SIZE="0.08333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21099" O_E="0.0" SE="0.1717960677340692" STUDY_ID="STD-Steele-1983" TOTAL_1="6" TOTAL_2="12" VAR="0.029513888888888888" WEIGHT="3.4061650727674397"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-07-30 16:53:26 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Third generation cephalosporins versus conventional antibiotics (high and low/middle-income countries)</NAME>
<DICH_OUTCOME CHI2="3.053519545951426" CI_END="0.022406955050208958" CI_START="-0.03261085610035258" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.0051019505250718125" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-1.6496171570633626" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.9999682417857709" P_Q="0.7058025923419982" P_Z="0.716227284001117" Q="0.14250583953557625" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="663" TOTAL_2="638" WEIGHT="100.0" Z="0.36350552924328433">
<NAME>Death</NAME>
<GROUP_LABEL_1>3 g cephalosporins</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 g cephalo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4899698672026498" CI_END="0.035184659128871885" CI_START="-0.03316202280501212" DF="8" EFFECT_SIZE="0.0010113181619298846" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-1.4536466520876894" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.9951121933377265" NO="1" P_CHI2="0.9928731503136332" P_Z="0.9537464515155262" STUDIES="9" TAU2="0.0" TOTAL_1="254" TOTAL_2="256" WEIGHT="39.267159151490425" Z="0.05800273307228798">
<NAME>High income countries</NAME>
<DICH_DATA CI_END="0.20805755281735927" CI_START="-0.20805755281735927" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21100" O_E="0.0" SE="0.10615376326222864" STUDY_ID="STD-Aronoff-1984" TOTAL_1="10" TOTAL_2="7" VAR="0.011268621454733284" WEIGHT="1.2741687021591512"/>
<DICH_DATA CI_END="0.07530797045640844" CI_START="-0.07530797045640844" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21101" O_E="0.0" SE="0.03842313994054385" STUDY_ID="STD-Barson-1985" TOTAL_1="27" TOTAL_2="23" VAR="0.0014763376828906165" WEIGHT="3.8432568539126173"/>
<DICH_DATA CI_END="0.1936386737243876" CI_START="-0.0987770136453362" EFFECT_SIZE="0.047430830039525695" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21102" O_E="0.0" SE="0.07459720935595282" STUDY_ID="STD-Congeni-1984" TOTAL_1="22" TOTAL_2="23" VAR="0.005564743643695856" WEIGHT="3.4794918018961964"/>
<DICH_DATA CI_END="0.048691892198775316" CI_START="-0.048691892198775316" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21103" O_E="0.0" SE="0.02484325864293974" STUDY_ID="STD-Del-Rio-1983" TOTAL_1="39" TOTAL_2="39" VAR="6.171875E-4" WEIGHT="6.034098925225123"/>
<DICH_DATA CI_END="0.0640625336898663" CI_START="-0.13813660776394038" EFFECT_SIZE="-0.037037037037037035" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21104" O_E="0.0" SE="0.05158236147417189" STUDY_ID="STD-Jacobs-1985" TOTAL_1="23" TOTAL_2="27" VAR="0.0026607400152521324" WEIGHT="3.8432568539126173"/>
<DICH_DATA CI_END="0.31275377483746203" CI_START="-0.31275377483746203" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21105" O_E="0.0" SE="0.15957118462605635" STUDY_ID="STD-Narciso-1983" TOTAL_1="5" TOTAL_2="5" VAR="0.02546296296296296" WEIGHT="0.7736024263109132"/>
<DICH_DATA CI_END="0.06649523956231998" CI_START="-0.04829341938030177" EFFECT_SIZE="0.0091009100910091" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21106" O_E="0.0" SE="0.029283359247430064" STUDY_ID="STD-Peltola-1989" TOTAL_1="101" TOTAL_2="99" VAR="8.575151288140479E-4" WEIGHT="15.470501321365642"/>
<DICH_DATA CI_END="0.12056853005506211" CI_START="-0.12056853005506211" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21107" O_E="0.0" SE="0.061515686515717274" STUDY_ID="STD-Steele-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.0037841796875" WEIGHT="2.32080727893274"/>
<DICH_DATA CI_END="0.10453735545339898" CI_START="-0.2156484665645101" EFFECT_SIZE="-0.05555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21108" O_E="0.0" SE="0.08168155755500968" STUDY_ID="STD-Wells-1984" TOTAL_1="12" TOTAL_2="18" VAR="0.006671876844612359" WEIGHT="2.2279749877754305"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6207318653103544" CI_END="0.030485895477594924" CI_START="-0.04859493289595472" DF="9" EFFECT_SIZE="-0.009054518709179896" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="36" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-1.515901043703685" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.9961480858558915" P_Z="0.6535614771535578" STUDIES="10" TAU2="0.0" TOTAL_1="409" TOTAL_2="382" WEIGHT="60.73284084850957" Z="0.4488200473446842">
<NAME>Low/middle income countries</NAME>
<DICH_DATA CI_END="0.31348446402870445" CI_START="-0.2023733529175933" EFFECT_SIZE="0.05555555555555555" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21109" O_E="0.0" SE="0.13159880003288793" STUDY_ID="STD-Bryan-1985" TOTAL_1="18" TOTAL_2="18" VAR="0.017318244170096024" WEIGHT="2.7849687347192877"/>
<DICH_DATA CI_END="0.16478692347043117" CI_START="-0.13978692347043115" EFFECT_SIZE="0.012499999999999997" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21110" O_E="0.0" SE="0.07769883766826889" STUDY_ID="STD-Filali-1993" TOTAL_1="16" TOTAL_2="20" VAR="0.006037109375" WEIGHT="2.750586404661025"/>
<DICH_DATA CI_END="0.17852137291231943" CI_START="-0.17852137291231943" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21111" O_E="0.0" SE="0.09108400680852977" STUDY_ID="STD-Girgis-1987" TOTAL_1="15" TOTAL_2="15" VAR="0.008296296296296296" WEIGHT="2.32080727893274"/>
<DICH_DATA CI_END="0.08677500150384146" CI_START="-0.20677500150384145" EFFECT_SIZE="-0.06" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21112" O_E="0.0" SE="0.07488658090739622" STUDY_ID="STD-Girgis-1988" TOTAL_1="50" TOTAL_2="50" VAR="0.005608" WEIGHT="7.736024263109133"/>
<DICH_DATA CI_END="0.18429815495132124" CI_START="-0.33429815495132126" EFFECT_SIZE="-0.07500000000000001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21113" O_E="0.0" SE="0.13229740801189818" STUDY_ID="STD-Haffejee-1988" TOTAL_1="16" TOTAL_2="15" VAR="0.017502604166666665" WEIGHT="2.395672029866054"/>
<DICH_DATA CI_END="0.04511476473603136" CI_START="-0.03768233230359894" EFFECT_SIZE="0.003716216216216213" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21114" O_E="0.0" SE="0.021122096551957903" STUDY_ID="STD-Nathan-2005" TOTAL_1="160" TOTAL_2="148" VAR="4.46142962750232E-4" WEIGHT="23.790786305249906"/>
<DICH_DATA CI_END="0.11058477996584293" CI_START="-0.10726252082963031" EFFECT_SIZE="0.0016611295681063093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21115" O_E="0.0" SE="0.055574312210281654" STUDY_ID="STD-Odio-1986" TOTAL_1="42" TOTAL_2="43" VAR="0.0030885041776458604" WEIGHT="6.574710503141221"/>
<DICH_DATA CI_END="0.15287456911596967" CI_START="-0.16968835642156024" EFFECT_SIZE="-0.008406893652795289" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21116" O_E="0.0" SE="0.08228797265711643" STUDY_ID="STD-Rodriguz-1985" TOTAL_1="61" TOTAL_2="39" VAR="0.006771310444018342" WEIGHT="7.361600688774651"/>
<DICH_DATA CI_END="0.1539830164746612" CI_START="-0.1539830164746612" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21117" O_E="0.0" SE="0.07856420714322282" STUDY_ID="STD-Sharma-1996" TOTAL_1="11" TOTAL_2="12" VAR="0.006172334644043224" WEIGHT="1.775922091705053"/>
<DICH_DATA CI_END="0.11256464966028347" CI_START="-0.1943828314784653" EFFECT_SIZE="-0.04090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21118" O_E="0.0" SE="0.078304367723058" STUDY_ID="STD-Tuncer-1988" TOTAL_1="20" TOTAL_2="22" VAR="0.006131574004507889" WEIGHT="3.241762548350494"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.283261669911646" CI_END="0.011699336588473927" CI_START="-0.0874019668443516" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.03785131512793884" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-1.9318387642481687" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="2" P_CHI2="0.8089496761589265" P_Q="0.44054493860324984" P_Z="0.13434133736434434" Q="0.594862951671429" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="247" TOTAL_2="254" WEIGHT="100.0" Z="1.4971995694995683">
<NAME>Deafness</NAME>
<GROUP_LABEL_1>3 g cephalosporins</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 g cephalo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.1141768702907235" CI_END="0.011286390385175628" CI_START="-0.1068492755133619" DF="5" EFFECT_SIZE="-0.04778144256409314" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" I2="2.232556151000561" ID="CMP-005.02.01" LOG_CI_END="-1.9474449319859306" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.40210575308698526" P_Z="0.11286101209070097" STUDIES="6" TAU2="0.0" TOTAL_1="192" TOTAL_2="188" WEIGHT="76.06023503434838" Z="1.585463726685627">
<NAME>Developed countries</NAME>
<DICH_DATA CI_END="0.20805755281735927" CI_START="-0.20805755281735927" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21119" O_E="0.0" SE="0.10615376326222864" STUDY_ID="STD-Aronoff-1984" TOTAL_1="10" TOTAL_2="7" VAR="0.011268621454733284" WEIGHT="3.3130865180272693"/>
<DICH_DATA CI_END="0.09114354932265722" CI_START="-0.47209593027503816" EFFECT_SIZE="-0.19047619047619047" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21120" O_E="0.0" SE="0.14368618098099162" STUDY_ID="STD-Barson-1985" TOTAL_1="21" TOTAL_2="15" VAR="0.020645718604902278" WEIGHT="7.040308850807948"/>
<DICH_DATA CI_END="0.07769244897094243" CI_START="-0.4184331897116832" EFFECT_SIZE="-0.1703703703703704" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21121" O_E="0.0" SE="0.1265649885906071" STUDY_ID="STD-Del-Rio-1983" TOTAL_1="27" TOTAL_2="30" VAR="0.01601869633694051" WEIGHT="11.433885050936217"/>
<DICH_DATA CI_END="0.0986044967412614" CI_START="-0.16549412884828482" EFFECT_SIZE="-0.03344481605351171" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21122" O_E="0.0" SE="0.06737333636554611" STUDY_ID="STD-Jacobs-1985" TOTAL_1="23" TOTAL_2="26" VAR="0.0045391664530250175" WEIGHT="9.81948616392572"/>
<DICH_DATA CI_END="0.05638329031243136" CI_START="-0.057260483294887504" EFFECT_SIZE="-4.3859649122807154E-4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21123" O_E="0.0" SE="0.028991291295076452" STUDY_ID="STD-Peltola-1989" TOTAL_1="96" TOTAL_2="95" VAR="8.404949709559757E-4" WEIGHT="38.41891800710156"/>
<DICH_DATA CI_END="0.17852137291231943" CI_START="-0.17852137291231943" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21124" O_E="0.0" SE="0.09108400680852977" STUDY_ID="STD-Steele-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.008296296296296296" WEIGHT="6.034550443549669"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04847872261013163" CI_END="0.08100162190152987" CI_START="-0.0936052344520456" DF="3" EFFECT_SIZE="-0.0063018062752578635" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="-1.0915062851234167" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.9972020629146561" P_Z="0.887494158076207" STUDIES="4" TAU2="0.0" TOTAL_1="55" TOTAL_2="66" WEIGHT="23.939764965651623" Z="0.14147569683108838">
<NAME>Developing countries</NAME>
<DICH_DATA CI_END="0.22766542754293492" CI_START="-0.2752844751619825" EFFECT_SIZE="-0.023809523809523808" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21125" O_E="0.0" SE="0.12830590425949714" STUDY_ID="STD-Bryan-1985" TOTAL_1="14" TOTAL_2="18" VAR="0.016462405067847245" WEIGHT="6.336277965727153"/>
<DICH_DATA CI_END="0.10931680180804859" CI_START="-0.10931680180804859" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21126" O_E="0.0" SE="0.055774903350431726" STUDY_ID="STD-Filali-1993" TOTAL_1="15" TOTAL_2="19" VAR="0.00311083984375" WEIGHT="6.7444975545555135"/>
<DICH_DATA CI_END="0.13849245446348968" CI_START="-0.13849245446348968" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21127" O_E="0.0" SE="0.07066071394979728" STUDY_ID="STD-Haffejee-1988" TOTAL_1="14" TOTAL_2="12" VAR="0.004992936495895076" WEIGHT="5.198997305212023"/>
<DICH_DATA CI_END="0.12919614117771058" CI_START="-0.12919614117771058" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21128" O_E="0.0" SE="0.06591760981160534" STUDY_ID="STD-Wells-1984" TOTAL_1="12" TOTAL_2="17" VAR="0.004345131283275048" WEIGHT="5.659992140156931"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.697431285406898" CI_END="0.018427153771098236" CI_START="-0.04249401030073343" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.012033428264817599" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-1.7345417400367316" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="3" P_CHI2="0.9972768119897383" P_Q="0.9719832223813919" P_Z="0.43876394308459965" Q="0.0012334878670233976" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="663" TOTAL_2="638" WEIGHT="100.0" Z="0.7742821848177367">
<NAME>Treatment failure</NAME>
<GROUP_LABEL_1>3 g cephalosporins</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 g cephalo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours conventional</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.192073615187002" CI_END="0.033506073441276846" CI_START="-0.058907233508450826" DF="8" EFFECT_SIZE="-0.012700580033586994" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="-1.4748764639195187" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.8393913523869838" P_Z="0.5900766223496094" STUDIES="9" TAU2="0.0" TOTAL_1="254" TOTAL_2="256" WEIGHT="39.26715915149043" Z="0.5387250011979444">
<NAME>Developed countries</NAME>
<DICH_DATA CI_END="0.20805755281735927" CI_START="-0.20805755281735927" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21129" O_E="0.0" SE="0.10615376326222864" STUDY_ID="STD-Aronoff-1984" TOTAL_1="10" TOTAL_2="7" VAR="0.011268621454733284" WEIGHT="1.2741687021591512"/>
<DICH_DATA CI_END="0.0997961707379672" CI_START="-0.31235655721139716" EFFECT_SIZE="-0.10628019323671498" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21130" O_E="0.0" SE="0.10514293405398581" STUDY_ID="STD-Barson-1985" TOTAL_1="27" TOTAL_2="23" VAR="0.011055036581480809" WEIGHT="3.8432568539126173"/>
<DICH_DATA CI_END="0.1936386737243876" CI_START="-0.0987770136453362" EFFECT_SIZE="0.047430830039525695" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21131" O_E="0.0" SE="0.07459720935595282" STUDY_ID="STD-Congeni-1984" TOTAL_1="22" TOTAL_2="23" VAR="0.005564743643695856" WEIGHT="3.4794918018961964"/>
<DICH_DATA CI_END="0.09384488580072844" CI_START="-0.04256283451867716" EFFECT_SIZE="0.02564102564102564" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21132" O_E="0.0" SE="0.03479852726768764" STUDY_ID="STD-Del-Rio-1983" TOTAL_1="39" TOTAL_2="39" VAR="0.0012109375" WEIGHT="6.034098925225123"/>
<DICH_DATA CI_END="0.07727396387362792" CI_START="-0.2125396643567197" EFFECT_SIZE="-0.06763285024154589" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21133" O_E="0.0" SE="0.07393340656164106" STUDY_ID="STD-Jacobs-1985" TOTAL_1="23" TOTAL_2="27" VAR="0.005466148605808909" WEIGHT="3.8432568539126173"/>
<DICH_DATA CI_END="0.31275377483746203" CI_START="-0.31275377483746203" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21134" O_E="0.0" SE="0.15957118462605635" STUDY_ID="STD-Narciso-1983" TOTAL_1="5" TOTAL_2="5" VAR="0.02546296296296296" WEIGHT="0.7736024263109132"/>
<DICH_DATA CI_END="0.08556252168364044" CI_START="-0.06896086151762386" EFFECT_SIZE="0.00830083008300829" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21135" O_E="0.0" SE="0.039419954759405025" STUDY_ID="STD-Peltola-1989" TOTAL_1="101" TOTAL_2="99" VAR="0.001553932833233539" WEIGHT="15.470501321365642"/>
<DICH_DATA CI_END="0.09966660313580787" CI_START="-0.2329999364691412" EFFECT_SIZE="-0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21136" O_E="0.0" SE="0.08486547258750168" STUDY_ID="STD-Steele-1983" TOTAL_1="15" TOTAL_2="15" VAR="0.0072021484375" WEIGHT="2.32080727893274"/>
<DICH_DATA CI_END="0.10453735545339898" CI_START="-0.2156484665645101" EFFECT_SIZE="-0.05555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21137" O_E="0.0" SE="0.08168155755500968" STUDY_ID="STD-Wells-1984" TOTAL_1="12" TOTAL_2="18" VAR="0.006671876844612359" WEIGHT="2.2279749877754305"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5115259768123195" CI_END="0.02868442663355924" CI_START="-0.05188858172138928" DF="9" EFFECT_SIZE="-0.011602077543915021" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="39" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="-1.5423538267078087" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.9970603588172215" P_Z="0.5724489882237445" STUDIES="10" TAU2="0.0" TOTAL_1="409" TOTAL_2="382" WEIGHT="60.73284084850956" Z="0.5644484324512076">
<NAME>Developing countries</NAME>
<DICH_DATA CI_END="0.3079786276332617" CI_START="-0.3079786276332617" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21138" O_E="0.0" SE="0.15713484026367722" STUDY_ID="STD-Bryan-1985" TOTAL_1="18" TOTAL_2="18" VAR="0.024691358024691357" WEIGHT="2.7849687347192877"/>
<DICH_DATA CI_END="0.16478692347043117" CI_START="-0.13978692347043115" EFFECT_SIZE="0.012499999999999997" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21139" O_E="0.0" SE="0.07769883766826889" STUDY_ID="STD-Filali-1993" TOTAL_1="16" TOTAL_2="20" VAR="0.006037109375" WEIGHT="2.750586404661025"/>
<DICH_DATA CI_END="0.17852137291231943" CI_START="-0.17852137291231943" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21140" O_E="0.0" SE="0.09108400680852977" STUDY_ID="STD-Girgis-1987" TOTAL_1="15" TOTAL_2="15" VAR="0.008296296296296296" WEIGHT="2.32080727893274"/>
<DICH_DATA CI_END="0.08677500150384146" CI_START="-0.20677500150384145" EFFECT_SIZE="-0.06" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21141" O_E="0.0" SE="0.07488658090739622" STUDY_ID="STD-Girgis-1988" TOTAL_1="50" TOTAL_2="50" VAR="0.005608" WEIGHT="7.736024263109133"/>
<DICH_DATA CI_END="0.18429815495132124" CI_START="-0.33429815495132126" EFFECT_SIZE="-0.07500000000000001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21142" O_E="0.0" SE="0.13229740801189818" STUDY_ID="STD-Haffejee-1988" TOTAL_1="16" TOTAL_2="15" VAR="0.017502604166666665" WEIGHT="2.395672029866054"/>
<DICH_DATA CI_END="0.04511476473603136" CI_START="-0.03768233230359894" EFFECT_SIZE="0.003716216216216213" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21143" O_E="0.0" SE="0.021122096551957903" STUDY_ID="STD-Nathan-2005" TOTAL_1="160" TOTAL_2="148" VAR="4.46142962750232E-4" WEIGHT="23.790786305249906"/>
<DICH_DATA CI_END="0.11058477996584293" CI_START="-0.10726252082963031" EFFECT_SIZE="0.0016611295681063093" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21144" O_E="0.0" SE="0.055574312210281654" STUDY_ID="STD-Odio-1986" TOTAL_1="42" TOTAL_2="43" VAR="0.0030885041776458604" WEIGHT="6.574710503141221"/>
<DICH_DATA CI_END="0.15287456911596967" CI_START="-0.16968835642156024" EFFECT_SIZE="-0.008406893652795289" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21145" O_E="0.0" SE="0.08228797265711643" STUDY_ID="STD-Rodriguz-1985" TOTAL_1="61" TOTAL_2="39" VAR="0.006771310444018342" WEIGHT="7.361600688774651"/>
<DICH_DATA CI_END="0.1539830164746612" CI_START="-0.1539830164746612" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21146" O_E="0.0" SE="0.07856420714322282" STUDY_ID="STD-Sharma-1996" TOTAL_1="11" TOTAL_2="12" VAR="0.006172334644043224" WEIGHT="1.775922091705053"/>
<DICH_DATA CI_END="0.11256464966028347" CI_START="-0.1943828314784653" EFFECT_SIZE="-0.04090909090909091" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="21147" O_E="0.0" SE="0.078304367723058" STUDY_ID="STD-Tuncer-1988" TOTAL_1="20" TOTAL_2="22" VAR="0.006131574004507889" WEIGHT="3.241762548350494"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-08-01 10:59:42 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2011-07-30 13:47:23 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot showing symmetry of risk difference (RD) against the standard error (SE) in individual studies</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-08-01 10:59:42 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-08-01 10:59:42 +1000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAR0AAANUCAIAAAABwG6hAAAnhUlEQVR42u3dsY4dSdnG8ZGQEMEE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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-07-29 13:04:20 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-07-29 13:04:20 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-07-29 13:04:20 +1000" MODIFIED_BY="[Empty name]">MEDLINE and CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-07-29 13:02:50 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>MEDLINE (OVID) </B>
<BR/>1 exp Meningitis/<BR/>2 (bacteria* adj2 meningit*).tw.<BR/>3 1 or 2<BR/>4 exp Cephalosporins/<BR/>5 cephalosporin*.tw,nm.<BR/>6 Ceftriaxone/<BR/>7 ceftriaxon*.tw,nm.<BR/>8 exp Cefotaxime/<BR/>9 cefotaxim*.tw,nm.<BR/>10 Ceftazidime/<BR/>11 ceftazidim*.tw,nm.<BR/>12 Cefmenoxime/<BR/>13 cefmenoxim*.tw,nm.<BR/>14 Ceftizoxime/<BR/>15 ceftizoxim*.tw,nm.<BR/>16 Moxalactam/<BR/>17 moxalactam*.tw,nm.<BR/>18 cefodizim*.tw,nm.<BR/>19 or/4-18<BR/>20 3 and 19</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-07-29 12:59:06 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-07-29 12:59:06 +1000" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-04-06 12:12:24 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>EMBASE (EMBASE.com)</B>
<BR/>13. #9 AND #12<BR/>12. #10 OR #11<BR/>11. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR 'cross-over':ab,ti OR volunteer*:ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEAR/2 (blind* OR mask*)):ab,ti<BR/>10. 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp<BR/>9. #3 AND #8<BR/>8. #4 OR #5 OR #6 OR #7<BR/>7. ceftriaxone:ab,ti OR cefotaxime:ab,ti OR ceftazidime:ab,ti OR cefmenoxime:ab,ti OR ceftizoxime:ab,ti OR latamoxef:ab,ti OR moxalactam:ab,ti OR cefodizime:ab,ti<BR/>6. 'ceftriaxone'/de OR 'cefotaxime'/de OR 'ceftazidime'/de OR 'cefmenoxime'/de OR 'ceftizoxime'/de OR 'latamoxef'/de OR 'cefodizime'/de<BR/>5. cephalosporin*:ab,ti<BR/>4. 'cephalosporin derivative'/exp<BR/>3. #1 OR #2<BR/>2. (meningit* NEAR/2 bacteria*):ab,ti<BR/>1. 'meningitis'/exp</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-07-29 12:55:12 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-07-29 12:52:28 +1000" MODIFIED_BY="[Empty name]">Details of previous search</TITLE>
<APPENDIX_BODY MODIFIED="2011-07-29 12:55:12 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2007, issue 1) which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (January 1966 to March 2007); and EMBASE (January 1974 to March 2007). We also searched the reference list of review articles and book chapters, and contacted experts for any unpublished trials. We imposed no language or publication restrictions.</P>
<P>We searched MEDLINE and CENTRAL using the following keywords and MeSH terms. We searched the MEDLINE terms in combination with the highly sensitive search strategies designed by The Cochrane Collaboration for identifying RCTs (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>). We searched EMBASE using an amended version of this strategy.</P>
<P>
<B>MEDLINE (OVID) </B>
<BR/>1 exp MENINGITIS/<BR/>2 exp Meningitis, Bacterial/<BR/>3 (bacteria$ adj meningit$).mp.<BR/>4 or/1-3<BR/>5 exp CEPHALOSPORINS/<BR/>6 cephalosporin$.mp.<BR/>7 exp CEFTRIAXONE/<BR/>8 exp CEFOTAXIME/<BR/>9 exp CEFTAZIDIME/<BR/>10 exp CEFMENOXIME/<BR/>11 exp CEFTIZOXIME/<BR/>12 exp MOXALACTAM/<BR/>13 (ceftraxone or cefotaxime or ceftazidime or cefmenoxime or cefodizime or ceftizoxime or moxalactam).mp.<BR/>14 or/5-13<BR/>15 4 and 14</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>